# Chapter 130: Major or Mild Neurocognitive Disorder Due to Prion Disease

## The Biological and Neurological Basis of Major or Mild Neurocognitive Disorder Due to Prion Disease

## Introduction

Major or Mild Neurocognitive Disorder Due to Prion Disease represents a category of rare, rapidly progressive, and invariably fatal neurodegenerative conditions (Dudhatra et al., 2012; Fox & Picillo, 2016). These disorders, also known as transmissible spongiform encephalopathies (TSEs), are unique in their etiology, stemming from the misfolding of a native cellular protein, the prion protein (PrP<sup>c</sup>), into a pathogenic, infectious isoform (PrP<sup>Sc</sup>) (Giubilei & Orzi, 2014; Hajj et al., 2012). This process initiates a cascade of neurodegeneration that is far more aggressive than that seen in more common proteinopathies such as Alzheimer's or Parkinson's disease (PD) (Cuenca‐Bermejo et al., 2019; Sherer et al., 2001). The resulting clinical syndrome is characterized by a swift decline in cognitive and motor function, often accompanied by a complex array of neurological and psychiatric symptoms (Kim et al., 2019; Presečki et al., 2014).

From a biological perspective, prion diseases are fundamentally disorders of protein conformation (Orsini et al., 2019). The accumulation of PrP<sup>Sc</sup> leads to widespread neuronal death, synaptic dysfunction, spongiform change, and gliosis, which are the pathological hallmarks of the disease (Bigio, 2021; Dickson, 2005). The clinical presentation is remarkably heterogeneous, reflecting the specific brain regions affected by the pathological process (Fox & Picillo, 2016). Manifestations can range from a rapidly progressive dementia (Knight, 2010) to cerebellar ataxia, myoclonus, parkinsonism, and various neuropsychiatric disturbances (Kim et al., 2019; Orsini et al., 2019). The cognitive impairment can be severe enough to meet criteria for major neurocognitive disorder, profoundly interfering with daily functioning, or it can manifest as a milder deficit, consistent with mild neurocognitive disorder (MCI) in its early stages (Presečki et al., 2014; Ibrahim & Amar, 2007).

The diagnostic journey is often challenging, as the initial symptoms can be nonspecific and mimic a wide range of other neurological and psychiatric conditions (Bagaeва et al., 2018; Filatov et al., 2020). For instance, early psychiatric symptoms may be misdiagnosed as primary mood or psychotic disorders (Chambers, 1955; Peterson & Martin, 1973), while initial motor symptoms can be confused with atypical parkinsonian syndromes (Tysnes & Vilming, 2008; Lees, 2005). The rapid progression, however, is a key clinical clue that distinguishes prionopathies from most other neurodegenerative disorders (Fox & Picillo, 2016; Knight, 2010). This chapter will provide a comprehensive overview of the biological and neurological underpinnings of this devastating group of diseases, exploring the mechanisms from the molecular and cellular level to the disruption of large-scale neural circuits that ultimately produce the profound clinical syndrome.

## Neurobiological Systems

The profound and rapid neurological decline in prion disease is a direct consequence of widespread dysfunction across multiple neurobiological systems (Saviluoto et al., 2020). The accumulation of pathogenic PrP<sup>Sc</sup> does not target a single neurotransmitter system but instead causes a global disruption of brain homeostasis, affecting neurotransmission, neural circuits, and autonomic function (Gerlach & Riederer, 1993).

### Neurotransmitter Systems and Neuropharmacology

While the primary pathology is protein misfolding, the clinical symptoms are mediated by downstream effects on various neurotransmitter systems (Schneider & Abou‐Saleh, 2002). The involvement of subcortical structures, particularly the basal ganglia, often leads to a parkinsonian phenotype characterized by rigidity and bradykinesia (Sethi, 2002; Tisel & Klassen, 2021). This suggests a profound disruption of the nigrostriatal dopaminergic system, analogous to that seen in Parkinson's disease (PD) (Gerlach & Riederer, 1993; Rabbani et al., 2023; Shults, 2003). The loss of dopaminergic neurons or dysfunction of dopamine signaling pathways likely contributes to the motor deficits and may also play a role in neuropsychiatric symptoms such as apathy and depression (Chakraborty & Diwan, 2022; Weintraub & Burn, 2011). Indeed, some patients present with a clinical picture that can be difficult to distinguish from other causes of parkinsonism in the early stages (Tysnes & Vilming, 2008; Bech et al., 2017).

The serotonergic and noradrenergic systems are also heavily implicated, particularly in the context of the mood and behavioral disturbances that are common in prion disease (Maas, 1979; Van Praag & Korf, 1975). Degeneration of brainstem nuclei such as the raphe nuclei (serotonin) and locus coeruleus (noradrenaline) is a feature of the neuropathology (Braak & Tredici, 2008; Dickson, 2005). Disruption of these pathways is thought to be a primary driver of depression, anxiety, and sleep-wake cycle disturbances (Kaji & Hirata, 2012; Santiago, 2016; Thase, 1998), symptoms that can be prominent and early features of the disease (Provini et al., 2005). The central cholinergic system, critical for attention and memory, is also compromised, contributing significantly to the cognitive decline and dementia (Sagar, 1996; Kim et al., 2012). This cholinergic deficit may explain why some cognitive symptoms in prion disease share features with other dementias where cholinergic loss is a key factor (Kholin et al., 2024; Emre, 2003).

Furthermore, there is evidence of altered glutamatergic signaling, which may contribute to neuronal excitotoxicity, a common pathway of cell death in neurodegenerative diseases (Doppler et al., 2024; Gasparini et al., 2015). The myoclonus, a characteristic feature of many prion diseases, may arise from cortical hyperexcitability, potentially linked to an imbalance between excitatory (glutamatergic) and inhibitory (GABAergic) systems (Murueta‐Goyena et al., 2019; Szabó & Kasteleijn, 2022). This hyperexcitability can manifest as seizures, which are a known complication (Pratibha, 2010; Sibley, 1974).

### Brain Regions, Neural Circuits, and Functional Connectivity

Prion pathology does not affect the brain uniformly; rather, it shows a predilection for certain regions, leading to distinct clinical syndromes (Grabowski & Damásio, 2004). The pattern of involvement often includes the cerebral cortex, basal ganglia, thalamus, and cerebellum (Dickson, 2005; Pillon et al., 1996).

Cortical involvement is responsible for the rapidly progressive dementia, which can manifest with deficits in executive function, language, and visuospatial processing (Kerchner & Rosenbloom, 2014; Presečki et al., 2014; Wilbur, 2023). Spongiform changes and neuronal loss in the frontal and temporal lobes disrupt the large-scale networks essential for higher cognitive functions (Grabowski & Damásio, 2004; Ovsiew, 1993). This can lead to profound personality changes, apathy, and disinhibition (Marin & Wilkosz, 2005; Godefroy et al., 2016).

Damage to the basal ganglia, particularly the striatum (caudate and putamen) and thalamus, underlies the motor symptoms, including parkinsonism and other movement disorders like dystonia and chorea (Fahn et al., 2009; Pauls & Timmermann, 2014). These structures are key nodes in the cortico-striato-thalamo-cortical loops that regulate motor control, and their disruption leads to the characteristic poverty or excess of movement seen in different prion disease subtypes (Marsden, 1984; Yanagisawa, 1998). Functional neuroimaging studies in related disorders have demonstrated how dysfunction in these circuits correlates with motor and cognitive deficits (Snow, 2003; Grachev, 2013).

Cerebellar involvement is also prominent, particularly in certain genetic forms of prion disease and in a subset of sporadic cases. This leads to ataxia, characterized by incoordination of gait, limbs, and speech (Mochizuki & Ugawa, 2019; Carlow & Bicknell, 1978). The pathology involves extensive loss of Purkinje cells and granular neurons, disrupting the cerebellum's role in coordinating and fine-tuning movement (Andrés, 2006).

### Autonomic Nervous System

Autonomic dysfunction is a frequently overlooked but significant component of prion disease (Mathias & Low, 2020; McLeod & Tuck, 1987). Pathological changes have been documented in central autonomic control centers in the brainstem and hypothalamus, as well as in the peripheral autonomic nervous system (Braak & Tredici, 2008; Kaufmann & Biaggioni, 2003). Clinical manifestations can include orthostatic hypotension, bladder and bowel dysfunction, and abnormal sweating (Cohen & Gross, 1990; Goldstein, 2002; Wada, 2019). These symptoms contribute significantly to patient morbidity and can complicate management (Parkes et al., 1987). The presence of autonomic failure can be a clue to a neurodegenerative process and requires careful evaluation (Kaufmann & Biaggioni, 2003; Low, 1998). In some cases, autonomic neuropathy may be a prominent feature, suggesting widespread involvement of the nervous system (Gudesblatt et al., 1985; McLeod, 1993).

## Genetic and Molecular Basis

At the core of prion disease is a molecular process of protein misfolding that is self-propagating (Giubilei & Orzi, 2014). This distinguishes it from other neurodegenerative disorders, although emerging evidence suggests that similar "prion-like" mechanisms of protein aggregate spreading may be at play in diseases like Alzheimer's and Parkinson's (Kuwabara & Yokota, 2011; Candela et al., 2013).

### Molecular Mechanisms: The Prion Protein Conversion

The central molecular event in all prion diseases is the conformational conversion of the normal cellular prion protein, PrP<sup>c</sup>, into the abnormal, disease-causing isoform, PrP<sup>Sc</sup> (Dudhatra et al., 2012). PrP<sup>c</sup> is a glycoprotein found on the surface of many cells, particularly neurons, though its precise function remains elusive (Hajj et al., 2012). It is rich in α-helical structure and is readily degraded by proteases (Fonseca Ornelas, 2016). In contrast, PrP<sup>Sc</sup> has a high β-sheet content, making it insoluble in detergents and resistant to protease degradation (Dudhatra et al., 2012; Hajj et al., 2012).

The conversion process is thought to be a template-directed refolding, where an existing PrP<sup>Sc</sup> molecule (or oligomer) acts as a template, binding to a normal PrP<sup>c</sup> molecule and inducing it to refold into the pathogenic PrP<sup>Sc</sup> conformation (Giubilei & Orzi, 2014). This initiates an exponential, chain-reaction-like process, leading to the accumulation of PrP<sup>Sc</sup> aggregates in the brain (Fonseca Ornelas, 2016; Hajj et al., 2012). These aggregates are neurotoxic, leading to synaptic dysfunction, neuronal apoptosis, and the characteristic spongiform (sponge-like) appearance of the brain tissue upon histopathological examination (Bigio, 2021; Dickson, 2005). The accumulation of these abnormal protein aggregates is a shared feature with other neurodegenerative diseases, which are collectively termed proteinopathies (Bencze et al., 2017; Goedert et al., 2003; Galpern & Lang, 2006).

### Genetic Factors and Heritability

Approximately 10-15% of human prion diseases are hereditary, caused by autosomal dominant mutations in the prion protein gene (PRNP) located on chromosome 20 (Dudhatra et al., 2012; Hajj et al., 2012). Over 50 different pathogenic mutations have been identified, which are believed to destabilize the structure of PrP<sup>c</sup>, making it more prone to spontaneously convert to the PrP<sup>Sc</sup> form (Vogel, 1985). Different mutations are associated with distinct clinical and pathological phenotypes, giving rise to specific genetic prion diseases such as familial Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker (GSS) syndrome, and Fatal Familial Insomnia (FFI) (Provini et al., 2005; Provini et al., 2007). The variability in clinical expression linked to specific genetic defects is a phenomenon seen across many neurological disorders (Jen, 2015; Vogel, 1985).

In addition to causative mutations, a common polymorphism at codon 129 of the PRNP gene, which can encode either methionine (M) or valine (V), is a major determinant of susceptibility and phenotype in all forms of prion disease (sporadic, genetic, and acquired) (Hajj et al., 2012). Homozygosity (M/M or V/V) at this codon is a significant risk factor for developing sporadic CJD and is associated with a more rapid disease course (Dudhatra et al., 2012). This genetic influence on disease susceptibility and progression highlights the complex interplay between genetic predisposition and the stochastic events that trigger protein misfolding in sporadic cases (Vogel, 1985).

### Cellular and Synaptic Mechanisms

The accumulation of PrP<sup>Sc</sup> triggers a cascade of downstream pathological events at the cellular level. A key early event is synaptic dysfunction (Bencze et al., 2017). PrP<sup>Sc</sup> aggregates are found at synapses, where they are thought to impair synaptic transmission and plasticity, contributing to the early cognitive and neurological deficits long before widespread neuronal death occurs (Xiao & Cheng, 2009).

As the disease progresses, overt neuronal loss becomes prominent (Bigio, 2021; Agid & Blin, 2007). The mechanisms of neuronal death are multifactorial and include apoptosis (programmed cell death) and possibly other regulated cell death pathways (Ruberg et al., 1997; Yang et al., 2021). The accumulation of misfolded proteins triggers endoplasmic reticulum stress and the unfolded protein response, which, when overwhelmed, can initiate apoptotic pathways (Trimmer et al., 1996; Jian-shen, 2012). Mitochondrial dysfunction and oxidative stress are also implicated as key players in the neurodegenerative process, a common theme in many age-related brain disorders (Ravenhill et al., 2023; Trimmer et al., 1996; Betarbet & Greenamyre, 2007).

Another cardinal feature is spongiform degeneration, which refers to the formation of small, empty vacuoles in the neuropil, giving the gray matter a sponge-like appearance (Hassin, 1941). This is thought to result from the swelling of neuronal processes and astrocytic swelling (Davison, 1940; Hassin, 1941). Accompanying this is a robust glial response, including astrogliosis and microglial activation (Guedes & Silva, 2010; Ravenhill et al., 2023). While this neuroinflammatory response may initially be a protective reaction, chronic activation of microglia can become detrimental, releasing pro-inflammatory cytokines and reactive oxygen species that contribute to neuronal damage (Guedes & Silva, 2010; Najjar et al., 2013).

## Brain Structure and Function

The relentless progression of prion disease is mirrored by dramatic changes in brain structure and function, which can be visualized using neuroimaging and electrophysiological techniques. These tools are crucial for diagnosis, for differentiating prion diseases from other rapidly progressive dementias, and for understanding the underlying pathophysiology (Knight, 2010; Fukuda et al., 2016).

### Neuroimaging Findings

Structural neuroimaging, particularly Magnetic Resonance Imaging (MRI), is a cornerstone of the diagnostic workup (Grachev, 2013). In the early stages of the disease, the MRI may be normal (Fox & Picillo, 2016). However, as the disease progresses, characteristic abnormalities often emerge. The most specific findings are hyperintensities on Diffusion-Weighted Imaging (DWI) and Fluid-Attenuated Inversion Recovery (FLAIR) sequences in the cerebral cortex (often called "cortical ribboning") and/or the deep gray matter, including the basal ganglia (caudate and putamen) and thalamus (Andrés, 2006; Grachev, 2013). These signal changes are thought to reflect the underlying spongiform degeneration and gliosis (Hassin, 1941). The pattern of these abnormalities can sometimes help distinguish between different subtypes of prion disease (Knight, 2010).

In addition to these signal changes, progressive and often remarkably rapid brain atrophy is a common finding (Uchida et al., 2024). This volume loss affects both gray and white matter and becomes more pronounced in later stages of the illness (Gertz, 2001; Uchida et al., 2024). While atrophy is a nonspecific finding seen in many neurodegenerative disorders (Dickson, 2005), its rapid rate of progression is a key feature in prion disease (Fox & Picillo, 2016). In some cases, white matter lesions are also observed, reflecting secondary axonal degeneration or primary myelin pathology (Ratai et al., 2012).

Functional neuroimaging techniques, such as Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT), can detect abnormalities even before structural changes are apparent on MRI (Teune & Leenders, 2012). These studies typically reveal patterns of regional cerebral hypometabolism or hypoperfusion that correspond to the areas of neuronal dysfunction and loss (Grachev, 2013; Abou‐Saleh, 2002). The specific pattern of hypometabolism can vary but often involves the cortex, basal ganglia, and cerebellum, reflecting the clinical symptomatology (Arnaldi et al., 2012; Teune & Leenders, 2012).

### Electrophysiological Findings

The electroencephalogram (EEG) is another critical diagnostic tool, particularly in sporadic CJD (Jordan, 1999). Although early EEG findings may be nonspecific, showing only diffuse slowing, a characteristic pattern of periodic sharp wave complexes (PSWCs) emerges in about two-thirds of patients as the disease progresses (Brigo & Mecarelli, 2019; Jordan, 1999). These complexes consist of high-amplitude, sharp, or triphasic waves that occur periodically, typically at a frequency of 1-2 Hz (Brigo & Mecarelli, 2019). The appearance of PSWCs is highly specific for sporadic CJD, though they can be seen in other encephalopathies (Brigo & Mecarelli, 2019; Magalhaes et al., 2014). The presence of PSWCs is thought to reflect severe cortical and subcortical dysfunction (Jordan, 1999). In other forms of prion disease, such as variant CJD or FFI, these typical EEG changes are usually absent (Knight, 2010). The EEG is also crucial for ruling out nonconvulsive status epilepticus, which can present with a similar picture of rapid cognitive decline and altered consciousness (Drislane, 2013; Jordan, 1999).

## Developmental Neurobiology

Prion diseases are fundamentally disorders of neurodegeneration, not neurodevelopment (Thibaut, 2018). Unlike conditions such as autism or certain forms of epilepsy that arise from abnormalities in early brain formation (Ciaranello & Ciaranello, 1995; Sarnat, 1987), prion diseases affect a brain that has, in most cases, developed normally (Agid & Blin, 2007). The onset of symptoms typically occurs in mid-to-late adulthood, after decades of normal neurological function (Dudhatra et al., 2012).

However, a developmental neurobiological perspective is relevant in several contexts. First, the age of onset varies significantly across different prion diseases, from childhood and adolescence in rare genetic and acquired forms to late life in sporadic CJD (Rich, 2001; Vanier, 2010). This suggests that age-related factors may influence the stochastic event of initial PrP<sup>c</sup> misfolding or the rate of disease progression (Morris & McManus, 1991). The aging brain may have diminished capacity to clear misfolded proteins or to compensate for neuronal dysfunction, creating a more vulnerable substrate for the disease process (Rinn, 1988).

Second, rare cases of prion disease with juvenile onset highlight the devastating impact of this pathogenic process on a still-maturing nervous system (Vanier, 2010). While the primary pathogenic mechanism is the same, the clinical expression in younger individuals can be atypical, often dominated by psychiatric symptoms or cerebellar ataxia rather than dementia (Rich, 2001). This differs from classic neurodevelopmental disorders where the primary issue is a disruption of critical developmental milestones (Steinhausen & Gillberg, 2006; Gordon, 1993).

Third, the normal expression and function of PrP<sup>c</sup> are regulated throughout development (Davison, 1977). While its role is not fully understood, it is implicated in processes such as myelination, synaptic plasticity, and neuronal survival (Hajj et al., 2012). It is conceivable that the disease process, by sequestering and depleting the pool of normal PrP<sup>c</sup>, could interfere with these ongoing maintenance and plasticity functions, thereby exacerbating the neurodegenerative cascade (Møller, 2001). This loss of a potentially neuroprotective or trophic function of PrP<sup>c</sup>, combined with the direct toxicity of PrP<sup>Sc</sup>, could contribute to the rapid and widespread neuronal death characteristic of these diseases (Bigio, 2021). Thus, while not a disease of development, prion disease represents a catastrophic failure of the biological mechanisms that maintain neuronal and network integrity throughout life (Agid & Blin, 2007).

## Treatment Mechanisms

Currently, there are no effective disease-modifying therapies that can halt or reverse the progression of prion disease (Fox & Picillo, 2016). The rapid and aggressive nature of the neurodegeneration poses a significant challenge for therapeutic intervention (Dudhatra et al., 2012). Consequently, management is entirely symptomatic and supportive, aimed at palliating distressing symptoms and improving the patient's quality of life (Feddersen, 2017).

The biological basis of these interventions targets the downstream consequences of the disease rather than the core pathogenic mechanism of PrP<sup>Sc</sup> propagation (Butler & Tolleson, 2014). For example, myoclonus, which can be severe and disabling, is often treated with antiepileptic drugs that enhance GABAergic inhibition, such as clonazepam, or with other agents like sodium valproate (Erro Aguirre & Navarro Azpiroz, 2009; Munsat, 1977; Pardo, 1997). The rationale is to dampen the cortical hyperexcitability that is thought to generate the myoclonic jerks (Szabó & Kasteleijn, 2022).

Psychiatric symptoms such as agitation, anxiety, depression, and psychosis are managed with psychotropic medications (Factor et al., 1995; Fénelon, 2005). The choice of agent is often empirical, drawing on treatments used for these symptoms in other neurological disorders (Weintraub & Burn, 2011; Fernandez & Friedman, 2000). For example, selective serotonin reuptake inhibitors (SSRIs) may be used for depression and anxiety (Kaji & Hirata, 2012), while atypical antipsychotics are employed for psychosis (Factor et al., 1995; Fénelon, 2005). However, patients with prion disease can be exquisitely sensitive to the side effects of these medications, particularly extrapyramidal symptoms from antipsychotics, which can worsen underlying parkinsonism (Factor et al., 1995; Mendez, 2001).

Parkinsonian features like rigidity and bradykinesia are sometimes treated with dopaminergic agents such as levodopa, but the response is typically poor and transient, unlike in idiopathic Parkinson's disease (Sethi, 2002; Thobois & Broussolle, 2005). This is likely because the pathology in prion-related parkinsonism involves not only the substantia nigra but also extensive postsynaptic damage in the striatum, rendering dopamine replacement less effective (Dickson, 2005; Pillon et al., 1996).

Research into disease-modifying therapies is actively ongoing. Strategies under investigation include developing compounds that can stabilize the normal PrP<sup>c</sup> structure, prevent its conversion to PrP<sup>Sc</sup>, or enhance the clearance of PrP<sup>Sc</sup> from the brain (Hajj et al., 2012). Immunotherapy, using antibodies to target PrP<sup>Sc</sup>, is another promising avenue (Kumar, 2011). However, translating these preclinical findings into effective human therapies remains a formidable challenge (Poewe, 2006).

## Future Directions

Despite significant advances in understanding the fundamental molecular biology of prion diseases, major questions and challenges remain. Future research must focus on several key areas to translate this basic knowledge into clinical benefit.

A primary goal is the development of reliable, non-invasive, and early diagnostic biomarkers (Knight, 2010). Current definitive diagnosis often requires brain tissue analysis post-mortem (Bencze et al., 2017). While MRI and EEG are helpful, they often only become characteristic in later stages (Jordan, 1999; Grachev, 2013). The development of ultrasensitive assays like Real-Time Quaking-Induced Conversion (RT-QuIC), which can detect minute amounts of PrP<sup>Sc</sup> in cerebrospinal fluid and even other tissues, represents a major breakthrough (Knight, 2010). Further refinement and validation of these techniques, and their application to more accessible samples like blood or urine, are critical for early and accurate diagnosis, which will be essential for the effective implementation of any future therapies (Dutta, 2021; Seibyl, 2022).

Elucidating the precise mechanisms of PrP<sup>Sc</sup> neurotoxicity is another vital area of investigation. While it is clear that PrP<sup>Sc</sup> accumulation leads to neuronal death, the specific molecular pathways linking the protein aggregates to synaptic failure, apoptosis, and neuroinflammation are not fully understood (Guedes & Silva, 2010; Bigio, 2021; Jian-shen, 2012). A deeper understanding of these processes could reveal novel therapeutic targets aimed at mitigating the downstream consequences of prion propagation, even if the initial misfolding event cannot be stopped (Butler & Tolleson, 2014).

The greatest challenge remains the development of effective disease-modifying therapies (Poewe, 2006). The prion-like spread of pathology poses a unique problem, as any therapeutic agent would need to efficiently cross the blood-brain barrier and halt the exponential replication of PrP<sup>Sc</sup> throughout the central nervous system (Fymat, 2017; Kuwabara & Yokota, 2011). Promising strategies include antisense oligonucleotides to reduce the production of the PrP<sup>c</sup> substrate, small molecules to inhibit the conversion process, and immunotherapies to clear existing PrP<sup>Sc</sup> (Hajj et al., 2012). Clinical trials for these approaches are in early stages but offer the first real hope for treating this devastating class of diseases.

Finally, understanding the heterogeneity of prion diseases is crucial. Why different PRNP mutations or different PrP<sup>Sc</sup> "strains" lead to such varied clinical phenotypes—from the insomnia of FFI to the ataxia of GSS and the dementia of CJD—is a fundamental unanswered question (Provini et al., 2005; Vanier, 2010). Answering this will not only improve our understanding of prion biology but may also provide insights into the selective vulnerability of different neuronal populations and circuits across the spectrum of neurodegenerative diseases (Trimmer et al., 1996).

## Conclusion

Major or Mild Neurocognitive Disorder Due to Prion Disease encompasses a group of disorders defined by a unique and terrifying biological mechanism: the templated misfolding and aggregation of the prion protein (Hajj et al., 2012). This process of self-propagation results in a rapidly progressive neurodegeneration that is unmatched in its speed and severity by other common dementias (Fox & Picillo, 2016; Knight, 2010). The underlying pathology is a cascade of events beginning at the molecular level with protein conversion, which translates into cellular dysfunction, synaptic loss, and widespread neuronal death (Bigio, 2021; Giubilei & Orzi, 2014).

The clinical manifestations are a direct reflection of the brain regions and neural circuits that are progressively destroyed. The involvement of the cerebral cortex, basal ganglia, cerebellum, and brainstem gives rise to a complex and variable syndrome of cognitive impairment, movement disorders, and neuropsychiatric symptoms (Kim et al., 2019; Pillon et al., 1996). While our understanding of these clinicopathological correlations has advanced significantly through neuroimaging and electrophysiology, the ability to intervene in this relentless process remains elusive (Grachev, 2013; Jordan, 1999).

Current management is restricted to symptomatic palliation, which provides limited relief and does not alter the fatal course of the disease (Feddersen, 2017). The future of prion disease research and clinical care hinges on the development of early and specific biomarkers and the translation of promising preclinical therapeutic strategies into effective treatments for patients (Dutta, 2021; Poewe, 2006). Prion diseases, though rare, have provided a powerful paradigm for understanding protein misfolding in neurodegeneration, offering lessons that extend far beyond their own devastating scope and into the broader landscape of human brain disorders (Galpern & Lang, 2006; Kuwabara & Yokota, 2011).


## References

1. Aarsland, D., & Svenningsson, P. (2012). Using biomarkers to disentangle different causes of Parkinsonism. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2012-303025
2. Abbasi, S., Velickovic, M., & Brin, M. F. (2001). MYOCLONUS. The Neurologist. https://doi.org/10.1097/00127893-200105000-00004
3. Abou‐Saleh, M. T. (2002). Neuro‐imaging. Neuro‐imaging Studies of Depression. https://doi.org/10.1002/0470846410.ch73
4. Adler, C. H., & Beach, T. G. (2016). Neuropathological basis of nonmotor manifestations of Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.26605
5. Adler, C. M., DelBello, M. P., & Strakowski, S. M. (2006). Brain Network Dysfunction in Bipolar Disorder. CNS Spectrums. https://doi.org/10.1017/s1092852900020800
6. Aggarwal, S. (2020). Pseudobulbar Affect or Depression - A Clinician’s Dilemma. Journal of Advanced Research in Psychology & Psychotherapy. https://doi.org/10.24321/2581.5822.201914
7. Agid, Y., & Blin, J. (2007). Nerve Cell Death in Degenerative Diseases of the Central Nervous System: Clinical Aspects. Novartis Foundation symposium. https://doi.org/10.1002/9780470513422.ch2
8. Aguirre, M. E. E., & Azpiroz, M. D. C. N. (2009). Mioclonías: características clínicas y neurofisiológicas, etiología y tratamiento. Revista de Neurología. https://doi.org/10.33588/rn.48s01.2008741
9. Al-Balawi, T., Al-Greeshah, F., & Khan, S. (2003). Management of status epilepticus.. PubMed.
10. Aldskogius, H., & Kozlova, E. N. (2013). Microglia and Neuropathic Pain. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/18715273113126660168
11. Ali, N., Syeda, A., Topgyal, T., Gaur, N. A., & Islam, A. (2021). Parkinson’s Disease: A Current Perspectives on Parkinson’s Disease and Key Bioactive Natural Compounds as Future Potential Drug Candidates. Current Drug Targets. https://doi.org/10.2174/1389450122666210623115505
12. AlJadir, S. J. (2020). Brain Catastrophe presented with endocrine disruption. Endocrinology&Metabolism International Journal. https://doi.org/10.15406/emij.2020.08.00289
13. Amina, S., Houda, B., Naoual, D., & Mohammed, C. (2022). MEADOWS SYNDROME: UNUSUAL, MULTI-FACTORIAL AND POTENTIALLY SERIOUS DISEASE: ABOUT 5 CLINICAL CASES. International Journal of Advanced Research. https://doi.org/10.21474/ijar01/14378
14. Anand, A., Bolishetti, N., Teja, B. N., Adhikari, S., Ahmed, I., & Natarajan, J. (2022). Neurodegenerative Disorder of Ageing using Neural Networks. 2022 International Conference on Applied Artificial Intelligence and Computing (ICAAIC). https://doi.org/10.1109/icaaic53929.2022.9793136
15. Andrés, C. D. (2006). Unusual magnetic resonance imaging and cerebrospinal fluid findings in paraneoplastic cerebellar degeneration: a sequential study. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2005.073379
16. Ansari, M. H. K., Rafiee, K., Emamgholipour, S., & Fallah, M. (2012). Migraine: Molecular Basis and Herbal Medicine. InTech eBooks. https://doi.org/10.5772/32018
17. Antonini, A. (2009). Non-motor Symptoms in Parkinson’s Disease. European Neurological Review. https://doi.org/10.17925/enr.2009.04.01.25
18. Antulić, M. (2019). Komplementarni fizioterapijski pristupi kod osoba s Parkinsonovom bolesti.
19. Apostolovska, E., & Krstev, T. (2021). KINESITHERAPY AND REHABILITATION OF CHILDREN WITH CEREBRAL PALSY. Knowledge International Journal.
20. Appenzeller, S., Veilleux, M., & Clarke, A. E. (2009). Third cranial nerve palsy or pseudo 3rd nerve palsy of myasthenia gravis? A challenging diagnosis in systemic lupus erythematosus. Lupus. https://doi.org/10.1177/0961203308101546
21. Araújo, R. C. B., Gomes, R. M., & Barbosa, M. U. F. (2017). A IMPORTÂNCIA DO BOBATH EM PACIENTES COM PARALISIA CEREBRAL.
22. Aripova, N. F., & Omonova, U. T. (2024). CLINICAL CASE OF MULTISYSTEM ATROPHY WITH PARKINSONISM. The American Journal of Medical Sciences and Pharmaceutical Research. https://doi.org/10.37547/tajmspr/volume06issue07-05
23. Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and Treatment of Parkinson Disease. JAMA. https://doi.org/10.1001/jama.2019.22360
24. Arnaldi, D., Morbelli, S., Morrone, E., Campus, C., & Nobili, F. (2012). Cognitive impairment in degenerative parkinsonisms: role of radionuclide brain imaging.. PubMed.
25. Arora, R., & Khan, Y. S. (2021). Motor Neuron Disease.
26. Asuku, A. O., Ayinla, M. T., Olajide, T. S., Ajagun, E. J., Ganiyu, K. O., Hamza, Y. O., Ajibare, A. J., & Abdulsalam, T. A. (2024). Diagnosis and Biomarkers of Parkinson's Disease. CRC Press eBooks. https://doi.org/10.1201/9781003402893-15
27. Atagün, M. İ., Balaban, Ö. D., Altınbaş, K., Yeşilyurt, S., & Tan, D. (2010). Clinic determinents of cognitive dysfunctions and cognitive endophenotypes in bipolar disorder. Dusunen Adam The Journal of Psychiatry and Neurological Sciences. https://doi.org/10.5350/dajpn2010230407t
28. Auer, R. N., Laganière, J., Robitaille, Y., Richardson, J. B., Dion, P. A., Rouleau, G. A., & Shekarabi, M. (2016). KCC3 axonopathy: neuropathological features in the central and peripheral nervous system. Modern Pathology. https://doi.org/10.1038/modpathol.2016.90
29. Augusto, J. (2012). Neuroimaging in Epileptic Disorders. InTech eBooks. https://doi.org/10.5772/22770
30. Auther, A. M., Gillett, D. A., & Cornblatt, B. A. (2008). Expanding the Boundaries of Early Intervention for Psychosis: Intervening During the Prodrome. Psychiatric Annals. https://doi.org/10.3928/00485713-20080801-02
31. Autora, M. J. G. H., & Principal, C. J. S. C. T. (2021). PROPUESTA DE EVALUACIÓN E INTERVENCIÓN NEUROPSICOLÓGICA EN UN CASO DE MUTISMO ACINÉTICO ANTERIOR.
32. Axelrod, B. N. (2008). Fabrication of psychiatric symptoms: Somatoform and psychotic disorders. Psychology Press eBooks. https://doi.org/10.4324/9780203890042-23
33. Ayala, R. (2023). Caminar, hablar y morir. Caso inusual de lesión cerebral traumática. Revista de Educaci�n e Investigaci�n en Emergencias. https://doi.org/10.24875/reie.22000064
34. Ayerbe, I., & Négrevergne, M. (2005). [Vertigo and pathology of the cerebellospinal system].. PubMed.
35. Ayuso‐Mateos, J. L. (2012). Psychiatric aspects of infections. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0141
36. Bach, A. S., Oertel, W. H., & Bach, J.-P. (2010). Kognitive Defizite als Komorbidität neurologischer Erkrankungen. Nervenheilkunde. https://doi.org/10.1055/s-0038-1628839
37. Bach, F. W., Finnerup, N. S. B., & Jensen, T. S. (2006). [Neuropathic pain].. PubMed.
38. Bachasson, D. (2012). La fonction neuromusculaire dans les maladies chroniques : évaluation, impact clinique et réentraînement.
39. Bahtiyarca, Z. T., Karaahmet, Ö. Z., & ÇAKMAK, C. (2021). Postpartum Acute Brachial Plexus Neuritis Mimicking Anterior Interosseous Nerve Palsy. Fiziksel Tıp ve Rehabilitasyon Bilimleri Dergisi. https://doi.org/10.31609/jpmrs.2020-79940
40. Bakheit, A. M. O. (2006). Recognition of acute illness in people with chronic neurological disability. Postgraduate Medical Journal. https://doi.org/10.1136/pgmj.2005.040253
41. Bakvis, P. (2005). Psychogenic non epileptic seizures : towards an integration of psychogenic, cognitive and neurobiological aspects.
42. Ball, H. A., McWhirter, L., Ballard, C., Bhome, R., Blackburn, D., Edwards, M. J., Fleming, S. M., Fox, N. C., Howard, R., Huntley, J., Isaacs, J. D., Larner, A. J., Nicholson, T. R., Pennington, C., Poole, N., Price, G., Price, J. P., Reuber, M., Ritchie, C., ... Carson, A. (2020). Functional cognitive disorder: dementia’s blind spot. Brain. https://doi.org/10.1093/brain/awaa224
43. Balmaceda, C., & Korkin, E. (2003). Cancer and Cancer Treatment-Related Neuromuscular Disease. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-317-0_15
44. Bansal, R., Khilnani, G. C., Malhotra, O., & Bhatia, M. (2003). Critical illness polyneuropathy: how often do we diagnose it?. PubMed.
45. Barber, T. R., Muhammed, K., Drew, D., Lawton, M., Crabbe, M. J. C., Rolinski, M., Quinnell, T., Zaiwalla, Z., Ben‐Shlomo, Y., Husain, M., & Shulman, J. (2017). Apathy in rapid eye movement sleep behaviour disorder is common and under‐recognized. European Journal of Neurology. https://doi.org/10.1111/ene.13515
46. Barbosa, R., Postal, M., Costallat, L. T. L., Cendes, F., & Appenzeller, S. (2012). Cognitive Impairment in Systemic Lupus Erythematosus: Prevalence and Clinical Importance. Current Rheumatology Reviews. https://doi.org/10.2174/157339712801318975
47. Barry, S., Baird, G., Lascelles, K., Bunton, P., & Hedderly, T. (2011). Neurodevelopmental movement disorders - an update on childhood motor stereotypies. Developmental Medicine & Child Neurology. https://doi.org/10.1111/j.1469-8749.2011.04058.x
48. Baumann, A., & Sturzenegger, M. (2006). Neuropathie motrice multifocale (NMM) - Diagnostic difficile, confusion facile, traitement efficace. Forum Médical Suisse ‒ Swiss Medical Forum. https://doi.org/10.4414/fms.2006.06003
49. Bech, S., Haugbøl, S., & Winge, K. (2017). [Challenges in the differential diagnoses of parkinsonism].. PubMed.
50. Belli, H., Akbudak, M., Ural, C., & Kulacaoğlu, F. (2012). Solitary lesion in ponto-mesencephalic area related secondary mania: a case report.. PubMed.
51. Bencze, J., Simon, V., Bereczki, E., Majer, R., Varkoly, G., Murnyák, B., Kálmán, J., & Hortobágyi, T. (2017). A Lewy-testes demencia klinikai és neuropatológiai jellemzői | Clinical and neuropathological characteristics of dementia with Lewy bodies.
52. Benedetti, F. D. (2020). Diseases of the nervous system. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198843177.003.0011
53. Benedetti, F., Bernasconi, A., & Pontiggia, A. (2005). Depression and neurological disorders. Current Opinion in Psychiatry. https://doi.org/10.1097/01.yco.0000194147.88647.7f
54. Benny, R., Stephen, S., & Alexander, S. E. E. (2022). A Challenging Rare Motor Neuron Disease to Diagnose. International Journal of Research and Review. https://doi.org/10.52403/ijrr.20221203
55. Benson, C., & Lusardi, P. (1995). Neurologic Antecedents to Patient Falls. Journal of Neuroscience Nursing. https://doi.org/10.1097/01376517-199512000-00003
56. Bergman, H., & Deuschl, G. (2002). Pathophysiology of Parkinson's disease: From clinical neurology to basic neuroscience and back. Movement Disorders. https://doi.org/10.1002/mds.10140
57. Berman, T., & Bayati, A. (2018). What are Neurodegenerative Diseases and How Do They Affect the Brain?. Frontiers for Young Minds. https://doi.org/10.3389/frym.2018.00070
58. Berrios, G. E. (1985). Presbyophrenia: Clinical Aspects. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.147.1.76
59. Bersani, F. S., Mellon, S. H., Reus, V. I., & Wolkowitz, O. M. (2019). Accelerated aging in serious mental disorders. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0000000000000525
60. Betarbet, R., & Greenamyre, J. T. (2007). Rotenone Model for Parkinson’s Disease. CRC Press eBooks. https://doi.org/10.3109/9781420019223-25
61. Beydoun, S. R., Rison, R. A., & Commins, D. J. (2001). Secondary amyloidosis as a life‐ending event in multifocal motor neuropathy. Muscle & Nerve. https://doi.org/10.1002/mus.1162
62. Biercewicz, M., & Ćwiękała-Lewis, K. (2024). Sleep Assessment in Parkinson’s Disease – An Assessment Tool. The Journal of Neurological and Neurosurgical Nursing. https://doi.org/10.15225/pnn.2024.13.3.6
63. Bigio, M. R. D. (2021). Neuronal Death. Cambridge University Press eBooks. https://doi.org/10.1017/9781316671863.030
64. Blanc, F., & Verny, M. (2017). Prodromal stage of disease (dementia) with Lewy bodies, how to diagnose in practice?. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2017.0675
65. Bleck, T. P. (2006). Neurological Disorders in the Intensive Care Unit. Seminars in Respiratory and Critical Care Medicine. https://doi.org/10.1055/s-2006-945531
66. Bogucki, A., Gajos, A., & Cybertowicz, M. (2006). Stany nagłe w pozapiramidowych zaburzeniach ruchowych - diagnostyka i postępowanie.
67. Bonnet, M. (2001). Symptômes de la maladie de Parkinson. Gérontologie et société. https://doi.org/10.3917/gs.097.0129
68. Boone, K. B. (2008). Fixed Belief in Cognitive Dysfunction Despite Normal Neuropsychological Scores: Neurocognitive Hypochondriasis?. The Clinical Neuropsychologist. https://doi.org/10.1080/13854040802441135
69. Bourgeois, P., Rivest, J., & Bocti, C. (2014). Rheumatoid meningitis presenting with stroke-like episodes. Neurology. https://doi.org/10.1212/wnl.0000000000000366
70. Boussaïd, G. (2016). Impact de la prise en charge respiratoire chez les patients atteints d'une maladie neuromusculaire.
71. Braak, H., & Tredici, K. D. (2008). Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology. https://doi.org/10.1212/01.wnl.0000312279.49272.9f
72. Brashear, A., Sweadner, K. J., Cook, J., Swoboda, K. J., & Ozelius, L. J. (2014). ATP1A3-Related Neurologic Disorders. University of Washington, Seattle eBooks.
73. Brey, R. L. (2005). Both migraine and motion sickness may be due to low brain levels of serotonin. Neurology. https://doi.org/10.1212/01.wnl.0000176949.34080.64
74. Brieger, P. (2005). Comorbidity in mixed states and rapid-cycling forms of bipolar disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544019.013
75. Brigo, F., & Mecarelli, O. (2019). Systemic and Dismetabolic Disorders. Clinical Electroencephalography. https://doi.org/10.1007/978-3-030-04573-9_42
76. Britton, T. C. (1995). Essential tremor and its variants. Current Opinion in Neurology. https://doi.org/10.1097/00019052-199508000-00012
77. Brna, T. G., & Wilson, C. C. (1990). Psychogenic amnesia.. PubMed.
78. Brown, S. L. (2006). Deterioration. Epilepsia. https://doi.org/10.1111/j.1528-1167.2006.00682.x
79. Brunasso, L., Costanzo, R., Cascio, A., Florena, A. M., Sparacia, G., Iacopino, D. G., & Grasso, G. (2021). Seizure in isolated brain cryptococcoma: Case report and review of the literature. Surgical Neurology International. https://doi.org/10.25259/sni_805_2020
80. Brás, J., Sousa, R. C. D., Costa, A. L., Melo, B., Marques, A., Teixeira, D., Pereira, C. A., & Cunha, N. (2019). A CASE OF NEUROLEPTIC MALIGNANT SYNDROME: A NEUROLOGIC EMERGENCY DUE TO PSYCHOTROPIC DRUGS. https://doi.org/10.26226/morressier.5d1a037357558b317a140392
81. Bueno, B. B., Soares, V. S., & Oliveira, C. F. D. (2014). Patologias associadas à deficiências na síntese do grupo heme. Revista Científica da FHO|Uniararas. https://doi.org/10.55660/revfho.v2i2.101
82. Buncic, J. R. (1999). Systemic and Pharmacological Effects on near Vision. American Orthoptic Journal. https://doi.org/10.1080/0065955x.1999.11982183
83. Burn, D. J., & Yarnall, A. J. (2015). Motor symptoms and phenotype in patients with Parkinson’s disease dementia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199681648.003.0007
84. Burns, J. M., & Login, I. S. (2002). Confounding factors in diagnosing brain death: a case report. BMC Neurology. https://doi.org/10.1186/1471-2377-2-5
85. Butler, J. T., & Tolleson, C. (2014). New Targets for Treating the Underlying Pathophysiology and Nonmotor Aspects of Parkinson’s Disease. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527313666140917104850
86. Bılgıç, B., Hanağası, H., & Emre, M. (2014). Parkinson’s Disease Dementia. Neuropsychiatric symptoms of neurological disease. https://doi.org/10.1007/978-3-319-09537-0_3
87. Cadilha, R., Amorim, H., Pinto, M., Silveira, F., & Parada, F. (2017). An atypical and severe case of neuralgic amyotrophy. Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação. https://doi.org/10.25759/spmfr.244
88. Cadilha, R., Amorim, H., Pinto, M., Silveira, F., & Parada, F. (2017). Um Caso Atípico e Grave de Amiotrofia Neurálgica. Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação. https://doi.org/10.25759/spmfr.267
89. canovic, S. K. S. (2014). Motor Ocular Neuropathy Caused by Mefloquine. General Medicine Open Access. https://doi.org/10.4172/2327-5146.1000150
90. Capone, G. T., Royal, P., Ares, W. J., & Lanningan, E. (2007). Transtornos neuroconductuales en niños, adolescentes y adultos jóvenes con síndrome de Down. Revista Síndrome de Down: Revista española de investigación e información sobre el Síndrome de Down.
91. Capuano, A. W., Wilson, R. S., Leurgans, S. E., Sampaio, C., Barnes, L. L., Farfel, J. M., & Bennett, D. A. (2020). Neuroticism, negative life events, and dementia in older White and Black Brazilians. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.5491
92. Carlander, B., Vincent, T., Floch, A. L., Pageot, N., Camu, W., & Dauvilliers, Y. (2009). Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes. BMJ Case Reports. https://doi.org/10.1136/bcr.08.2008.0709
93. Carlow, T. J., & Bicknell, J. M. (1978). Abnormal Ocular Motility with Brainstem and Cerebellar Disorders. International Ophthalmology Clinics. https://doi.org/10.1097/00004397-197801810-00005
94. Carreón‐Rodríguez, A., & Pérez‐Martínez, L. (2012). Clinical implications of thyroid hormones effects on nervous system development.. PubMed.
95. Castro, L. G. D., Benavides-Villalobos, J. D., & Rodríguez, G. J. M. (2020). Síndrome opsoclonus - mioclonus. Revista Medica Sinergia. https://doi.org/10.31434/rms.v5i5.420
96. Ceballos-Picot, I., Jinnah, H. A., Torres, R. J., Visser, J. E., Schretlen, D. J., Verdú, A., Laróvere, L. E., Chen, C., Cossu, A., Wu, C., Sampat, R., Chang, S., Kremer, R. D. D., Nyhan, W. L., Harris, J. C., Reich, S. G., & Puig, J. (2010). Attenuated variants of Lesch-Nyhan disease. Brain. https://doi.org/10.1093/brain/awq013
97. Cekić, S., Stanković-Babić, G., Višnjić, Z., Jovanović, I., & Risimić, D. (2010). Optic Disc Abnormalities – Diagnosis, Evolution and Influence on Visual Acuity. Bosnian Journal of Basic Medical Sciences. https://doi.org/10.17305/bjbms.2010.2711
98. Celaya, L. V., Rodríguez, A. T., Pérez, J. R. G., Márquez, G. M., Toledo‐Cárdenas, M. R., Castilla, P. C., Manzo, J., Coria‐Ávila, G. A., & García, L. I. (2019). Enfermedad de Parkinson más allá de lo motor. eNeurobiología. https://doi.org/10.25009/eb.v10i23.2542
99. Chakraborty, A., & Diwan, A. (2022). Depression and Parkinson's disease: a Chicken-Egg story. AIMS neuroscience. https://doi.org/10.3934/neuroscience.2022027
100. Chambers, W. R. (1955). NEUROSURGICAL CONDITIONS MASQUERADING AS PSYCHIATRIC DISEASES. American Journal of Psychiatry. https://doi.org/10.1176/ajp.112.5.387
101. Charles, A. (2012). Migraine is not primarily a vascular disorder. Cephalalgia. https://doi.org/10.1177/0333102412441717
102. Chaudhary, M. A., & Rabheru, K. (2009). Síntomas paranoides en pacientes ancianos. RET: revista de toxicomanías.
103. Chaudhary, S., & Tyagi, N. (2022). A Review on Parkinson’s Disease: Overview and Management. International Journal of Pharmaceutical Sciences Review and Research. https://doi.org/10.47583/ijpsrr.2022.v76i01.004
104. Chaudhry, S. (2020). Depression and its Dilemma. IP Journal of Surgery and Allied Sciences. https://doi.org/10.18231/j.jsas.2020.013
105. Chiu, H., & Li, S. (1996). PROGRESSIVE SUPRANUCLEAR PALSY PRESENTING WITH PSYCHIATRIC FEATURES. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.1996.tb10025.x
106. Ciaranello, A., & Ciaranello, R. D. (1995). The Neurobiology of Infantile Autism. The Neuroscientist. https://doi.org/10.1177/107385849500100608
107. Clancy, Ú., Radaković, R., Doubal, F., Hernández, M. D. C. V., Maniega, S. M., Taylor, A. M., Corley, J., Chappell, F. M., Russ, T. C., Cox, S. R., Bastin, M. E., Deary, I. J., & Wardlaw, J. M. (2022). Are neuropsychiatric symptoms a marker of small vessel disease progression in older adults? Evidence from the Lothian Birth Cohort 1936. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.5855
108. Clark, D. J., Bond, C., Andrews, A. W., Müller, D. J., Sarkisian, A., Opoka, R. O., Idro, R., Bangirana, P., Witten, A., Sausen, N., Birbeck, G. L., John, C. C., & Postels, D. G. (2023). Admission Clinical and EEG Features Associated With Mortality and Long-term Neurologic and Cognitive Outcomes in Pediatric Cerebral Malaria. Neurology. https://doi.org/10.1212/wnl.0000000000207657
109. Clark, I. F., Brunet, D., & Noa, Y. P. (2012). LA EPILEPSIA EN UN PAÍS AFRICANO. PRESENTACIÓN DE UN PACIENTE. DOAJ (DOAJ: Directory of Open Access Journals).
110. Clarke, C. (2022). Multiple Sclerosis, Neuromyelitis Optica (Devic's) and Other Demyelinating Diseases. Neurology. https://doi.org/10.1002/9781119235699.ch11
111. Clarke, C. (2022). Neuropsychiatry. Neurology. https://doi.org/10.1002/9781119235699.ch22
112. Clavero, P., & Rodríguez‐Oroz, M. (2007). Trastornos del sueño en la enfermedad de Parkinson y otros trastornos del movimiento. Anales del Sistema Sanitario de Navarra. https://doi.org/10.4321/s1137-66272007000200013
113. Clinique, U. D. G., Debré, H. R., & Sérurier, B. (2004). Microcephalia vera and microcephaly with simplified gyral pattern.
114. Cohen, J. A., & Gross, K. (1990). Autonomic neuropathy: clinical presentation and differential diagnosis.. PubMed.
115. Constenla, I. R., Cabo, I., Lamas, P. B., & Pérez, E. M. C. (2010). Trastornos cognitivos y neuropsiquiátricos en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009737
116. Corboy, J. R. (2012). Call for submissions!. Neurology Clinical Practice. https://doi.org/10.1212/cpj.0b013e31824cb0cd
117. Cortés, M. D. C. M. (2013). Análisis evolutivo y valoración neuropsicológica integral de pacientes con deterioro cognitivo leve o enfermedad de Alzheimer..
118. Costa, F. A. D. O., Soares, P. H. A., Ferreira, B. K., Gago, G., & Gibbon, F. D. L. (2018). Neurodegeneration Associated with Pantothenate Kinase. Case reportNeurodegeneration Associated with Pantothenate Kinase. Case report. JBNC - JORNAL BRASILEIRO DE NEUROCIRURGIA. https://doi.org/10.22290/jbnc.v28i3.1671
119. Costanza, A., Amerio, A., Aguglia, A., Escelsior, A., Serafini, G., Berardelli, I., Pompili, M., & Amore, M. (2020). When Sick Brain and Hopelessness Meet: Some Aspects of Suicidality in the Neurological Patient. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527319666200611130804
120. Cruz, J. F. D., & Cruz, L. E. B. C. D. (2020). EXERCÍCIOS FÍSICOS PARA PARKINSON.. Fiep Bulletin - online. https://doi.org/10.16887/90.a1.8
121. Csóti, I., Fogel, W., Schade, S., Schnitzler, A., Südmeyer, M., Winkler, C., & Winkler, J. (2013). Schmerz bei Parkinson-Patienten. Aktuelle Neurologie. https://doi.org/10.1055/s-0033-1343339
122. Cubides-Diaz, D., Lazaro, V. N., Rey, M., Mantilla, K., & Cáceres, E. (2024). Encefalitis y demencia rápidamente progresiva por probable enfermedad priónica que se presenta con un estado epiléptico no convulsivo. Reporte de caso y revisión de la literatura. Revista Ecuatoriana de Neurologia. https://doi.org/10.46997/revecuatneurol33100115
123. Cuenca‐Bermejo, L., Gil-Martínez, A.-L., Cano-Fernandez, L., Sánchez-Rodrigo, C., Estrada, C., Fernández‐Villalba, E., & Herrero, M. T. (2019). Parkinson's disease: a short story of 200 years.. PubMed. https://doi.org/10.14670/hh-18-073
124. Dabiri, I., Calvo, N. E., Nauman, F., Pahlavanzadeh, M., & Burakgazi, A. Z. (2019). Atypical presentation of Lyme neuroborreliosis related meningitis and radiculitis. Neurology International. https://doi.org/10.4081/ni.2019.8318
125. Dalvi, A., Lyons, K. E., & Pahwa, R. (2012). Secondary dystonia. CRC Press eBooks. https://doi.org/10.3109/9781841848525-20
126. Daniele, A., & Albanese, A. (2012). Early visual memory deficits. Neurology. https://doi.org/10.1212/wnl.0b013e318253d67b
127. Das, J., Graham, L., Morris, R., Barry, G., Godfrey, A., Walker, R., & Stuart, S. (2022). Eye Movement in Neurological Disorders. Neuromethods. https://doi.org/10.1007/978-1-0716-2391-6_11
128. Davison, A. (1977). The Biochemistry of Brain Development and Mental Retardation. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.131.6.565
129. Davison, C. (1940). MYOCLONUS EPILEPSY. Archives of Neurology And Psychiatry. https://doi.org/10.1001/archneurpsyc.1940.02280030098009
130. Delgado, M. G., & Bogousslavsky, J. (2013). Aggravation neurologique après une crise d’épilepsie post-AVC : une paralysie de Todd persistante?.
131. DeMarco, E. F., & Blaivas, J. G. (1993). Voiding disorders. Current Opinion in Urology. https://doi.org/10.1097/00042307-199308000-00003
132. Demarquay, G., & Montavont, A. (2010). Migraine et épilepsie: symptômes cliniques communs, comorbidité et mécanismes physiopathologiques. Douleur et Analgésie. https://doi.org/10.1007/s11724-010-0206-8
133. Denny, M. C., Ramadan, A. R., Savitz, S. I., & Grotta, J. C. (2019). Neurological Deterioration in Acute Ischemic Stroke. Cambridge University Press eBooks. https://doi.org/10.1017/9781108759823.007
134. Derouesné, C. (1995). [Conversion hysteria].. PubMed.
135. Desai, J., & Mitchell, W. G. (2012). Acute Cerebellar Ataxia, Acute Cerebellitis, and Opsoclonus-Myoclonus Syndrome. Journal of Child Neurology. https://doi.org/10.1177/0883073812450318
136. Dhengare, A. S., & Fulmali, D. G. (2022). The Development of Psychiatric Illness and Chemoprophylaxis of Botulinum Toxin in Migraine: A Narrative Review. Cureus. https://doi.org/10.7759/cureus.32998
137. Dickson, D. (2005). Molecular neuropathology of parkinsonism. CRC Press eBooks. https://doi.org/10.1201/b14441-6
138. Dickson, D. W. (2005). Neuropathology of Parkinson's disease. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544873.040
139. Dickson, D. W., & Orr, C. (2011). Neuropathology of Dementia in Parkinson's Disease. Parkinson s Disease. https://doi.org/10.1002/9781444397970.ch14
140. Diguvinti, S., Quraishi, D. S. S., Harish, P. V., & Theja, D. C. R. (2014). Mickey Mouse sign and Humming Bird sign: Diagnostic Clue of Progressive Supranuclear Palsy. International Journal of Medical Research and Review. https://doi.org/10.17511/ijmrr.2014.i05.16
141. DiMario, F. J. (2009). Headache Syndromes. https://doi.org/10.1093/oso/9780195335378.003.0011
142. DiMario, F. J. (2009). Somatoform Disorder. https://doi.org/10.1093/oso/9780195335378.003.0008
143. Disher, M. J., Telian, S. A., & Kemink, J. L. (1991). Evaluation of acute vertigo: unusual lesions imitating vestibular neuritis.. PubMed.
144. DM, F. P. G. M., BSc, M. P. C. B., Boyd, D. M., & BSc, M. D. S. S. (2014). Major Medical Problems. https://doi.org/10.1002/9781118690345.ch8
145. Dogaru, G., & Stănescu, I. (2014). TREATMENT AND REHABILITATION IN NON-MOTORS SYMPTOMS OF PARKINSON’S DISEASE. Balneo Research Journal. https://doi.org/10.12680/balneo.2014.1076
146. Domingos, A., Silva, V., Correia, C., Rocha, L., Costa, T., Faria, M., & Mota, M. C. (2021). MO1023BARDET-BIEDL SYNDROME OR SENIOR-LOKEN SYNDROME? GOING BEYOND THE OBVIOUS. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfab108.0020
147. Domizio, P., & Martin, J. E. (2012). Neuromuscular and Mechanical Disorders of the Large Intestine. https://doi.org/10.1002/9781118399668.ch34
148. Domoto‐Reilly, K., Sapolsky, D., & Dickerson, B. C. (2014). Mild Cognitive Impairment (MCI) Stage of the Frontotemporal Dementias: Early Diagnosis and Management. Perspectives on Gerontology. https://doi.org/10.1044/gero19.2.57
149. Dongen, R. M. V., & Haan, J. (2019). Symptoms related to the visual system in migraine. F1000Research. https://doi.org/10.12688/f1000research.18768.1
150. Doppler, C. E. J., Seger, A., Farrher, E., Brambilla, C. R., Hensel, L., Filß, C., Hellmich, M., Gogishvili, A., Shah, N. J., Lerche, C., Neumaier, B., Langen, K., Fink, G. R., & Sommerauer, M. (2024). Glutamate Signaling in Patients With Parkinson Disease With REM Sleep Behavior Disorder. Neurology. https://doi.org/10.1212/wnl.0000000000209271
151. Dores, L. A., Simão, M. A., Marques, M. C., & Dias, O. (2014). Parésia do Nervo Motor Ocular Comum em Contexto de Sinusite Esfenoidal. Acta Médica Portuguesa. https://doi.org/10.20344/amp.5229
152. Došen, A. (2012). Psychiatric and behaviour disorders among adult persons with intellectual disability. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0246
153. Drake, M. E. (1987). Paroxysmal kinesigenic choreoathetosis in hyperthyroidism. Postgraduate Medical Journal. https://doi.org/10.1136/pgmj.63.746.1089
154. Drakulić, S. M., Aleksić, D., & Ljubisavljević, S. (2020). Recurrent Painful Ophthalmoplegic Neuropathy: Migraine, Neuralgia, or Something Else?. Journal of Oral & Facial Pain and Headache. https://doi.org/10.11607/ofph.2656
155. Drislane, F. W. (2013). Overlap of Encephalopathies and Epileptic Seizures. Journal of Clinical Neurophysiology. https://doi.org/10.1097/wnp.0b013e3182a73bfa
156. Dubois, B., Pillon, B., & Agid, Y. (1996). Testing cognition may contribute to the diagnosis of movement disorders. Neurology. https://doi.org/10.1212/wnl.46.2.329
157. Dudhatra, G., Kumar, A., Modi, C. M., Awale, M., Patel, H. B., & Mody, S. K. (2012). Transmissible Spongiform Encephalopathies Affecting Humans. ISRN Infectious Diseases. https://doi.org/10.5402/2013/387925
158. Duncan, J. S., Sander, J. W., Alim‐Marvasti, A., Balestrini, S., Baxendale, S., Bindman, D., Chinthapalli, K., Chowdhury, F. A., Diehl, B., Eriksson, S., Foong, J., Heaney, D., Khan, S., Koepp, M. J., Kullmann, D. M., Rajakulendran, S., Rugg‐Gunn, F., Sidhu, M. K., Sisodiya, S. M., ... Yogarajah, M. (2024). Epilepsy and Related Disorders. Neurology. https://doi.org/10.1002/9781119715672.ch10
159. Dutta, R. (2021). Role of neuron specific enolase as a biomarker in Parkinson’s disease. Journal of Neuroscience and Neurological Disorders. https://doi.org/10.29328/journal.jnnd.1001052
160. Dykhno, Y. А., & Shnayder, N. А. (2013). PARANEOPLASTIC LIMBIC ENCEPHALITIS IN NEUOROLOGICAL AND ONCOLOGICAL PRACTICE. Russian Journal of Oncology. https://doi.org/10.17816/onco39993
161. Dzugaeva, F. K., Shipilova, N. N., Farnieva, I. A., Isaeva, Z. S., & Batsoeva, D. O. (2024). Cognitive impairment in multiple system atrophy — exclusion criteria or an integral part of the clinical picture?. S S Korsakov Journal of Neurology and Psychiatry. https://doi.org/10.17116/jnevro202412404286
162. Dąbrowski, W., Siwicka-Gieroba, D., Gasinska-Blotniak, M., Zaid, S., Jezierska, M., Pakulski, C., Roberson, S. W., Ely, E. W., & Kotfis, K. (2020). Pathomechanisms of Non-Traumatic Acute Brain Injury in Critically Ill Patients. Medicina. https://doi.org/10.3390/medicina56090469
163. D’Arrigo, S., Bruzzone, M. G., Faravelli, F., Riva, D., & Pantaleoni, C. (2005). Progressive Encephalopathy with Edema, Hypsarrhythmia, and Optic Nerve Atrophy (PEHO)-Like Syndrome: What Diagnostic Characteristics Are Defining?. Journal of Child Neurology. https://doi.org/10.1177/08830738050200051801
164. Ebadi, M., Tippin, J., Chou, K. L., Erickson, B. A., Doerschug, K. C., & Fletcher, D. M. J. (2011). Non-motor Symptoms in Parkinson’s Disease. touchREVIEWS in Neurology. https://doi.org/10.17925/usn.2011.07.02.113
165. Ebadi, M., Tippin, J., Chou, K. L., Erickson, B. A., Doerschug, K. C., & Fletcher, D. M. J. (2012). Non-motor Symptoms in Parkinson’s Disease. European Neurological Review. https://doi.org/10.17925/enr.2012.07.01.35
166. Ehrenreich, H., & Sirén, A. (2002). Neuroprotection in schizophrenia - What does it mean? - What means do we have?. Steinkopff eBooks. https://doi.org/10.1007/978-3-642-57516-7_21
167. Elefante, C., Lattanzi, L., Ismail, Z., Medda, P., Bacciardi, S., Mainardi, C., & Perugi, G. (2019). Mild Behavioral Impairment: presentation of the diagnostic criteria and the Italian version of the MBI-Checklist.. PubMed. https://doi.org/10.1708/3142.31246
168. Ellis, R. J. B., Mbizvo, G. K., Jacob, A., Doran, M., & Larner, A. J. (2016). Relapsing polychondritis complicated by cognitive dysfunction: two distinct clinical phenotypes?. International Journal of Neuroscience. https://doi.org/10.3109/00207454.2016.1151880
169. El‐Mansoury, B., Maloui, A. B., Draoui, A., Hamdan, Y. A., Oukhrib, M., Smimih, K., Elmourid, A., Khiat, A. E., Boulbaroud, S., Meftah, I., Hammoud, M., Chatoui, R., Sabir, E., Gamrani, H., & Jayakumar, A. R. (2023). Non-Motor Symptoms in Parkinson's Disease. Advances in medical diagnosis, treatment, and care (AMDTC) book series. https://doi.org/10.4018/978-1-6684-5156-4.ch003
170. Emre, M. (2003). What causes mental dysfunction in Parkinson's disease?. Movement Disorders. https://doi.org/10.1002/mds.10565
171. Enders, J., Elliott, D. S., & Wright, D. E. (2022). Emerging Nonpharmacologic Interventions to Treat Diabetic Peripheral Neuropathy. Antioxidants and Redox Signaling. https://doi.org/10.1089/ars.2022.0158
172. Enrique, P. M. L., Gloria, A. S., Efraín, S. C. J., & Luis, G. A. J. (2019). Latencia diagnóstica en la enfermedad de Parkinson y su relación con los síntomas prodrómicos motores y no motores. eNeurobiología.
173. Erro, R., Santangelo, G., Barone, P., & Vitale, C. (2015). Nonmotor symptoms in Parkinson&amp;#39;s disease: classification and management. Journal of Parkinsonism and Restless Legs Syndrome. https://doi.org/10.2147/jprls.s44382
174. Esteban, L. A. T., Villalobos, P. S., & López, N. G. (2016). Manejo del dolor en un caso de neuromielitis óptica (enfermedad de Devic). Revista de la Sociedad Española del Dolor. https://doi.org/10.20986/resed.2016.3431/2016
175. EV, A., Swathilakshmi, S., & Vivek, D. (2020). Emerging Novel Drugs For Parkinson’s Disease. American Journal Of Pharmacy And Health Research. https://doi.org/10.46624/ajphr.2020.v8.i10.001
176. Evers, S., & Jensen, R. (2020). Headache and sleep. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198724322.003.0057
177. Fabbrni, B. L., & Cysneiros, R. M. (2018). As crises neonatais produzem efeitos neurológicos deletérios de longo prazo: evidências clínicas experimentais.
178. Factor, S. A. (2007). Levodopa. CRC Press eBooks. https://doi.org/10.3109/9781420019995-23
179. Factor, S. A., Molho, E., Podskalny, G. D., & Brown, D. (1995). Parkinson's disease: drug-induced psychiatric states.. PubMed.
180. Fahn, S., Greene, P., Ford, B., & Bressman, S. (2003). Movement Disorders. https://doi.org/10.1007/978-1-4757-4552-8_9
181. Fahn, S., Greene, P., Ford, B., Bressman, S., & Frucht, S. J. (2009). Movement Disorders. https://doi.org/10.1007/978-1-57340-359-7_9
182. Falchook, G. S., Malone, C., Upton, S., & Shandera, W. X. (2003). Postmalaria Neurological Syndrome after Treatment of Plasmodium falciparum Malaria in the United States. Clinical Infectious Diseases. https://doi.org/10.1086/375269
183. Feddersen, B. (2017). Palliative care in adults with glioma. Annals of Research Hospitals. https://doi.org/10.21037/arh.2017.08.07
184. Feldman, E. L., Bromberg, M. B., Blaivas, M., & Junck, L. (1991). Acute pandysautonomic neuropathy. Neurology. https://doi.org/10.1212/wnl.41.5.746
185. Felice, R., Samson, J., Carlino, P., Giuliani, M., & Fiore-Donno, G. (1991). [Psychogenic oral paresthesia].. PubMed.
186. Fenichel, G. M. (2005). Psychomotor Retardation and Regression.
187. Fernandez, H. H., & Friedman, J. H. (2012). Acute Parkinsonism. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-835-5_2
188. Fernandez, H. H., & Gálvez-Jiménez, N. (2012). Nonmotor complications of Parkinson disease. Cleveland Clinic Journal of Medicine. https://doi.org/10.3949/ccjm.79.s2a.03
189. Fernández, R. M. N., Miranda, Y. E., Sánchez, T. D. J. M., Oduardo, M. D. D., & Martínez, R. R. (2013). Miastenia grave y miastenia grave ocular. Revista cubana de oftalmología.
190. Fiar, Z., Hroudov, J., & Raboch, J. (2012). Neurotransmission in Mood Disorders. InTech eBooks. https://doi.org/10.5772/31831
191. Fierro, Á. D. J. L., Aparicio, S. Y. L., Morgado‐Valle, C., Beltrán‐Parrazal, L., García, L. I., Hernández‐Aguilar, M. E., Manzo, J., & Pérez-Estudillo, C. A. (2022). Trastornos de las neuronas motoras: causas, síntomas, factores de riesgo, diagnósticos y tratamientos. eNeurobiología. https://doi.org/10.25009/eb.v13i31.2599
192. Filatov, A., Khanni, J. L., Alusma-Hibbert, K., & Espinosa, P. S. (2020). Sporadic Creutzfeldt-Jakob Disease: Case Report and Literature Review. Cureus. https://doi.org/10.7759/cureus.7767
193. Finsterer, J., Zarrouk‐Mahjoub, S., & Daruich, A. (2015). The Eye on Mitochondrial Disorders. Journal of Child Neurology. https://doi.org/10.1177/0883073815599263
194. Firth, P. G., & Bolay, H. (2004). Transient High Altitude Neurological Dysfunction: An Origin in the Temporoparietal Cortex. High Altitude Medicine & Biology. https://doi.org/10.1089/152702904322963708
195. Fitten, L. J. (2015). Psychological Frailty in the Aging Patient. Nestlé Nutrition Institute Workshop series. https://doi.org/10.1159/000382060
196. Flanagan, M. E., Sonnen, J. A., Keene, C. D., Hevner, R. F., & Montine, T. J. (2017). Molecular Basis of Diseases of the Nervous System. Molecular Pathology. https://doi.org/10.1016/b978-0-12-802761-5.00029-8
197. Folkerth, R. D. (2021). Cerebral Cortical Migration Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9781316671863.041
198. Fontana, M. H., Scoppetta, C., Quadrini, R., Cesa, I. L., Lello, R. D., Peppe, A., Tolli, V. S., & Casali, C. (1991). [Miller Fisher syndrome: review of the literature and presentation of 2 cases].. PubMed.
199. Fox, S. H., & Picillo, M. (2016). A Rapidly Progressive Movement Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190607555.003.0028
200. Fox, S. H., & Picillo, M. (2016). Becoming a Little Forgetful. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190607555.003.0003
201. Freitas, T. M., & Santos, M. J. D. S. (2020). ATUAÇÃO DA FISIOTERAPIA RESPIRATÓRIA EM UM PACIENTE PEDIÁTRICO COM PNEUMONIA.
202. Friedman, J. H. (2012). Fatigue: A Common Comorbidity in Parkinson’s Disease. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-429-6_27
203. Friedman, J. H., & Fernandez, H. H. (2000). THE NONMOTOR PROBLEMS OF PARKINSONʼS DISEASE. The Neurologist. https://doi.org/10.1097/00127893-200006010-00004
204. Friedman, R. S., & Patel, S. P. (1997). Neuropsychiatric features of acute disseminated encephalomyelitis: a review. Journal of Neuropsychiatry. https://doi.org/10.1176/jnp.9.4.534
205. Fujita, M. (2005). [Secondary headache in children].. PubMed.
206. Fukuda, J. S., Pires, M. M., Fukuda, T. G., & Oliveira‐Filho, J. (2016). Atualização sobre diagnóstico e tratamento das demências rapidamente progressivas com base na experiência do Serviço. Revista Científica Hospital Santa Izabel. https://doi.org/10.35753/rchsi.v3i2.475
207. Funalot, B. (2014). Peripheral neuropathies in mitochondrial disorders. https://doi.org/10.1002/9781118618424.ch17
208. Fymat, A. L. (2017). Therapeutics Delivery Behind, Through and Beyond the Blood Brain Barrier. Open Access Journal of Surgery. https://doi.org/10.19080/oajs.2017.05.555654
209. Fénelon, G. (2005). [Management of psychiatric complications of Parkinson's disease].. PubMed.
210. Ga, C.-O. (2006). Paroxysmal neurogenetic and neurometabolic disorders.
211. Gaba, B., Kumar, S., Md, S., Baboota, S., Narang, J. K., & Ali, J. (2017). Natural Neuroprotectives for the Management of Parkinson's Disease. https://doi.org/10.1002/9783527803781.ch4
212. Gallo, B. V., & Hearron, A. C. (2017). Parkinson’s disease. Routledge eBooks. https://doi.org/10.4324/9781315382760-65
213. Galpern, W. R., & Lang, A. E. (2006). Interface between tauopathies and synucleinopathies: A tale of two proteins. Annals of Neurology. https://doi.org/10.1002/ana.20819
214. Gandhi, R., Caress, J. B., Rudnick, S., & Bonkovsky, H. L. (2021). Porphyric neuropathy. Muscle & Nerve. https://doi.org/10.1002/mus.27232
215. García, M. L., Mederos, L. M. P., & Alemán, I. G. (2010). Mielinolisis pontina central. Acta Médica del Centro.
216. Gardella, E., Tassinari, C. A., & Rubboli, G. (1995). Negative myoclonus.. PubMed.
217. Garg, S. K., Bala, K., Malhotra, H. S., Anthony, A., & Maheshwari, S. (2022). Non-motor Dysfunction in Idiopathic Parkinson’s Disease - An Indian Perspective. Acta Scientific Neurology. https://doi.org/10.31080/asne.2022.05.0524
218. Garnacho‐Montero, J., Madrazo-Osuna, J., a-Garmendia, J. L. G., & Ortíz-Leyba, C. (2001). Neuromuscular Disorders of the Critically Ill Patient. Clinical Pulmonary Medicine. https://doi.org/10.1097/00045413-200111000-00008
219. Gasparini, C., Smith, R., & Griffiths, L. R. (2015). Migraine and glutamate: modulators of glutamatergic signalling as potential treatments of neuropsychiatric disorders. Nova Science Publishers eBooks.
220. Genton, P., & Bureau, M. (2006). Progressive myoclonic epilepsies: myth or reality?. Epileptic Disorders. https://doi.org/10.1684/j.1950-6945.2006.tb00198.x
221. Gertz, H.-J. (2001). Dementias in Other Brain Diseases. Contemporary psychiatry. https://doi.org/10.1007/978-3-642-59519-6_74
222. Ghaemi, S. N. (2013). Understanding Mania and Depression. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780199579563.013.0047
223. Ghosh, J., & Ghosh, J. (2015). Can Devic Disease Involve Peripheral Nerves?. Journal of Pediatric Neurology. https://doi.org/10.1055/s-0035-1556834
224. Giubilei, F., & Orzi, F. (2014). Hetrogeneous pathologies associated with dementia in Parkinsonism share a prion-like spreading mechanism. ARCHIVES ITALIENNES DE BIOLOGIE. https://doi.org/10.12871/00039829201344
225. Giubilei, F., Candela, S. F., & Orzi, F. (2013). Heterogeneous pathologies associated with dementia in Parkinsonism share a prion-like spreading mechanism.. PubMed.
226. Gnanamuthu, C. P. (1990). Transient neurologic symptoms. Postgraduate Medicine. https://doi.org/10.1080/00325481.1990.11704630
227. Godefroy, O., Barbay, M., Andriuta, D., Tir, M., & Roussel, M. (2016). Global Hypoactivity and Apathy. Neuropsychiatric symptoms of neurological disease. https://doi.org/10.1007/978-3-319-39138-0_5
228. Goedert, M., Jakes, R., Crowther, R. A., & Spillantini, M. G. (2003). Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy as α-Synucleinopathies. Parkinson s Disease. https://doi.org/10.1385/1-59259-142-6:33
229. Gogoriță, C., Pruteanu, A., & Raduca, D. (2019). Methods and techniques used in mild mental retardation.
230. GOKCAL, E., & YILDIZ, G. B. (2015). Treatment of Motor Symptoms in Idiopathic Parkinson’s Disease. Bezmialem Science. https://doi.org/10.14235/bs.2015.503
231. Gold, B. G., Schnell, J. V., & Spencer, P. S. (2003). Neurotoxic Disorders. https://doi.org/10.1007/978-1-4757-4552-8_14
232. Goldberg, T. E., Berman, K. F., & Weinberger, D. R. (1995). Neuropsychology and neurophysiology of schizophrenia. Current Opinion in Psychiatry. https://doi.org/10.1097/00001504-199501000-00009
233. Goldstein, D. S. (2002). Dysautonomias: Clinical Disorders of the Autonomic Nervous System. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-137-9-200211050-00011
234. Gordillo, R., Muñoz, L. H., López, E. S., Hernández, M. J., Borreguero, P. M., Méndez, M. A. R., Sánchez, V., Granados, T. G., & Burgos, R. I. Q. (2010). Trastorno bipolar en la infancia de causa orgánica. Revista de Psiquiatría Infanto-Juvenil.
235. Gordon, C. (2013). SP0029 Adult neuropsychiatric lupus. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2012-eular.1504
236. Gordon, N. (1993). Neurological problems in childhood.
237. Goudie, F. (2017). Physical and Emotional Problems in Later Life. Routledge eBooks. https://doi.org/10.4324/9781315174075-3
238. Grabowski, T. J., & Damásio, A. R. (2004). Definition, clinical features and neuroanatomical basis of dementia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511526886.002
239. Grachev, I. D. (2013). Dopamine transporter imaging with [123I]FP-CIT (DaTSCAN) in Parkinson's disease with depressive symptoms: a biological marker for causal relationships?. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2013-305380
240. Grantika, P. A., Westa, W., & Samatra, D. P. G. P. (2015). ASPEK PSIKIATRI PADA PENYAKIT PARKINSON. Medicina-buenos Aires.
241. Graus, F., Rojas-Marcos, I., & Reñé, R. (2000). Síndromes paraneoplásicos en otoneuroftalmología. Revista de Neurología. https://doi.org/10.33588/rn.3112.2000234
242. Green, M. C., Sayers, G. M., & Shaffer, R. (2002). Heroin-induced leucoencephalopathy misdiagnosed as psychiatric illness. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.1080/136515002753489434
243. Greenberg, B. (2007). Neurology. https://doi.org/10.1093/oso/9780195188493.003.0010
244. Gregory, A., Kurian, M. A., Maher, E. R., Hogarth, P., & Hayflick, S. J. (2015). PLA2G6-Associated Neurodegeneration.
245. Grewal, J. S., Bril, V., Lewis, G. F., & Perkins, B. A. (2006). Objective Evidence for the Reversibility of Nerve Injury in Diabetic Neuropathic Cachexia. Diabetes Care. https://doi.org/10.2337/diacare.29.02.06.dc05-2177
246. Gruen, P., & Kline, D. G. (2007). Hypertrophic mononeuropathy. Neurosurgical FOCUS. https://doi.org/10.3171/foc.2007.22.6.24
247. Guadiana, I. C. D., Anguiano, M. G., & Carmona, F. S. (2017). Abordaje interdisciplinario en paciente adulto con parálisis cerebral infantil: Reporte de caso clínico.. Revista Mexicana de Estomatología.
248. Gudesblatt, M., Goodman, A., Rubenstein, A. E., Bender, A. N., & Choi, H.-S. H. (1985). Autonomic neuropathy associated with autoimmune disease. Neurology. https://doi.org/10.1212/wnl.35.2.261
249. Guedes, R. P., & Silva, C. (2010). Inflammation in the Pathogenesis and Progression of Neurological Diseases. Ciência em Movimento. https://doi.org/10.15602/1983-9480/cmbs.v12n24p35-47
250. Guerrini, R., & Pellacani, S. (2012). Benign childhood focal epilepsies. Epilepsia. https://doi.org/10.1111/j.1528-1167.2012.03609.x
251. Guo, J., Wang, J., Dove, A., Bennett, D., & Xu, W. (2024). Psychological well-being trajectories preceding incident mild cognitive impairment and dementia. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2024-333837
252. Gupta, R. D., & Appleton, R. (2001). Cerebral palsy: not always what it seems. Archives of Disease in Childhood. https://doi.org/10.1136/adc.85.5.356
253. Guthrie, E., & Nayak, A. (2012). Medically unexplained symptoms.
254. Gutmann, L., & Hopf, H. (1998). Critical-Illness-Neuropathie und -Myopathie. Aktuelle Neurologie. https://doi.org/10.1055/s-2007-1017709
255. Güç, B. U., Gümüş, A., Çekinmez, E. K., Özenli, Y., Yıldırım, S., & Tanır, G. (2009). Nöropsikiyatrik bulgularla başvuran nörobruselloz olgusu Olgu Sunumu. Türk Pediatri Arşivi. https://doi.org/10.4274/tpa.v44i3.5000002186
256. Hainline, B., Gurin, L., & Torres, D. M. (2019). Acute Concussion versus Second Impact Syndrome. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0005
257. Hainline, B., Gurin, L., & Torres, D. M. (2019). Chronic Traumatic Encephalopathy. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0036
258. Hainline, B., Gurin, L., & Torres, D. M. (2019). Cognitive Dysfunction Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0034
259. Hainline, B., Gurin, L., & Torres, D. M. (2019). Objective Biomarkers and Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0010
260. Hainline, B., Gurin, L., & Torres, D. M. (2019). Unmasking Neuropsychiatric Disorders Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0035
261. Hajj, G. N. M., Tiago, G., Casini, M., & Marilene, H. (2012). Transmissible Spongiform Encephalopathies. InTech eBooks. https://doi.org/10.5772/29586
262. Haken, R. V., & Hansen, H.-C. (2019). Delir erkennen in 3 Schritten. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/a-0767-9764
263. Han, S., Lee, O. Y., Yang, S. Y., Jun, D. W., Lee, H. L., Jeon, Y. C., Han, D. S., Sohn, J. H., Yoon, B. C., Choi, H. S., Hahm, J. S., Lee, M. H., Lee, D. H., & Kee, C. S. (2006). [A case of optic neuritis associated with Crohn's disease].. PubMed.
264. Hantoro, W. D., Setyaningsih, I., & Was’an, M. (2019). Patofisiologi parkinsonism pasca trauma kepala. https://doi.org/10.22146/bns.v18i2.54995
265. Haq, I. Z., Naidu, Y., Reddy, P., & Chaudhuri, К. R. (2010). Narcolepsy in Parkinson’s disease. Expert Review of Neurotherapeutics. https://doi.org/10.1586/ern.10.56
266. Hardman, S., & O'Mahony, E. (2022). Is there a role for melatonin in the treatment of schizophrenia?. Progress in Neurology and Psychiatry. https://doi.org/10.1002/pnp.755
267. Harrison, J., Stow, I., & Owen, A. M. (2001). Parkinson’s disease. CRC Press eBooks. https://doi.org/10.3109/9780203213193-13
268. Haslam, R. H. A. (1997). Nonfebrile Seizures. Pediatrics in Review. https://doi.org/10.1542/pir.18.2.39
269. Hassin, G. B. (1941). MULTIPLE DEGENERATIVE SOFTENING. Archives of Neurology And Psychiatry. https://doi.org/10.1001/archneurpsyc.1941.02280190011001
270. Hazazi, ‏. A., Alhakami, ‎. H., Alyami, F. H., Sharyah, S. M. S. A., Almalki, A. A., Almutairi, R. O., Alhasani, K. H., Altwaijri, A. A., Majrashi, A. Y., & Aljohani, M. A. (2021). Migraine Preventive Therapy; Focus on β-blockers; Literature Review. Pharmacophore. https://doi.org/10.51847/brdllootr4
271. Hedera, P., & Friedman, J. H. (2014). Can fall of blood pressure prevent falls in Parkinson disease?. Neurology. https://doi.org/10.1212/wnl.0000000000000370
272. Heimer, G., Gregory, A., Hogarth, P., Hayflick, S. J., & Zeev, B. B. (2019). MECR-Related Neurologic Disorder.
273. Henry, E., & Lai, E. C. (2003). Hypokinesia and Movement Challenges in Parkinson's Disease.
274. Hilton‐Jones, D., & Damian, M. S. (2006). Myopathies in the older patient. Reviews in Clinical Gerontology. https://doi.org/10.1017/s0959259807002158
275. Holmes, G. L. (1993). Benign Focal Epilepsies of Childhood. Epilepsia. https://doi.org/10.1111/j.1528-1167.1993.tb06259.x
276. Horoșan, L., Nistor, D.-E., & Teacoe, I. (2021). Multiple sclerosis and its psychiatric symptomatology. Romanian Journal of Psychiatry & Psychotherapy. https://doi.org/10.37897/rjpp.2021.3-4.3
277. Hp, K. (2011). Poststroke-Depression: Diagnostik, Epidemiologie, Verlauf und Ätiopathogenese. Journal für Neurologie, Neurochirurgie und Psychiatrie.
278. Hu, W., Liu, S., Gan, J., Li, Z., Shi, Z., Li, Y., & Ji, Y. (2019). Neurofibriilary tangle-predominant dementia. https://doi.org/10.3760/cma.j.issn.0254-9026.2019.11.030
279. Huang, C., Chu, C., Lin, Y., Lin, Y., Huang, H., & Chang, Y.-C. (2022). Retinopathy of Prematurity Is a Biomarker for Pathological Processes in the Immature Brain. Neonatology. https://doi.org/10.1159/000526652
280. Huecker, M., Bhutta, B. S., Dominique, E., & Bossuah, K. A. (2021). Adrenal Insufficiency (Nursing).
281. Hussain, E., Momin, A., Islam, M., Haque, S., Hossain, M. A., Chowdhury, R., & Hoque, A. (2016). Lafora Body Disease: A Rare Type of Progressive Myoclonic Epilepsy. American Journal of Medical Case Reports. https://doi.org/10.12691/ajmcr-4-3-2
282. Häfele, M. (2001). Internistische Differenzialdiagnose bei unklaren Bewusstseinsstörungen in Verbindung mit synkopalen Zuständen oder epileptischen Anfällen. Aktuelle Neurologie. https://doi.org/10.1055/s-2001-15333
283. Ibrahim, I. R., & Amar, K. (2007). Mild cognitive impairment. British Journal of Hospital Medicine. https://doi.org/10.12968/hmed.2007.68.10.27322
284. Inuzuka, T. (1996). [Paraneoplastic neurological syndrome: diagnosis and therapy].. PubMed.
285. Irakkam, M. P. B. D., Joseph, J. H. M., & Kandasamy, M. (2024). Aberrant Hippocampal Neuroregenerative Plasticity in Schizophrenia: Reactive Neuroblastosis as a Possible Pathocellular Mechanism of Hallucination. Neurosignals. https://doi.org/10.33594/000000712
286. İbiloğlu, A. O., Atlı, A., Kaya, M. C., Baran, A. S., & Sır, A. (2016). Psychogenic Gait Disorder After a Stressful Life Event: Case Report. Turkiye Klinikleri Journal of Case Reports. https://doi.org/10.5336/caserep.2015-46732
287. Jain, K. K. (2019). Introduction. Springer protocols handbooks/Springer protocols. https://doi.org/10.1007/978-1-4939-9465-6_1
288. James, T., & Somashekhar, L. M. (2021). Psychosis in Children and Young People. Child and Adolescent Mental Health. https://doi.org/10.4324/9781003083139-52
289. Jang, E. H., Lee, J. K., Jang, H. J., Kim, M., & Chung, S. J. (2012). A Case of Multiple System Atrophy-Cerebellar Type Preceded by Dementia. Journal of Movement Disorders. https://doi.org/10.14802/jmd.12011
290. Jarne, L. P., Romero, M. C., Gil, B. A., Sáez, M. D. P. G., Aguirre, L. M. G., & Jarne, M. E. P. (2021). Atrapamiento del nervio pudendo. A propósito de un caso.. Revista Sanitaria de Investigación.
291. Jayasekara, H., Wickramarathne, J. S., Liyanage, D. S., & Jayasinghe, P. A. (2024). Opsoclonus-myoclonus-ataxia syndrome associated with bacterial urinary tract infection. BMJ Case Reports. https://doi.org/10.1136/bcr-2024-261533
292. Jellinger, K. A. (2011). Postencephalitic Parkinsonism. https://doi.org/10.1002/9781444341256.ch19
293. Jellinger, K. A. (2024). Mild cognitive impairment in Parkinson's disease: current view. Frontiers in Cognition. https://doi.org/10.3389/fcogn.2024.1369538
294. Jen, J. C. (2015). Familial Hemiplegic Migraine.
295. Jenkins, T. M., Brockington, A., & Shaw, P. J. (2020). The motor neuron diseases. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0604
296. Jeong, B. J., Lee, K. S., Choong, E. J., Hwang, J. S., & Kim, Y. H. (2002). A Case of Antenatally Detected Schizencephaly.. Obstetrics & Gynecology Science.
297. Jhamnani, K., Shivakumar, V., Kalmady, S. V., Rao, N. P., & Venkatasubramanian, G. (2013). Successful Use of Add-on Minocycline for Treatment of Persistent Negative Symptoms in Schizophrenia. Journal of Neuropsychiatry. https://doi.org/10.1176/appi.neuropsych.11120376
298. Jian-shen, S. (2012). Role of Neuronal Apoptosis in Parkinson Disease. Medical Recapitulate.
299. Jiang, H., Xu, Z.-X., & Li-Ke (2009). Poststroke cognitive impairment. Int J Cerebrovasc Dis. https://doi.org/10.3760/cma.j.issn.1673-4165.2009.08.011
300. Jiménez, A., Organista‐Juárez, D., Rocha, L., Estudillo, E., Fernández-Sánchez, V., Cureño-Díaz, M. A., Guzmán‐Ruiz, M. A., & Guevara‐Guzmán, R. (2024). Dysfunction of olfactory structures: A conserved mechanism of neurodegeneration?. Brain Behavior and Immunity Integrative. https://doi.org/10.1016/j.bbii.2024.100053
301. Jiménez, M. S. B., & Salgado, M. D. (2001). Demencia en pacientes con parálisis supranuclear progresiva. Revista de Neurología. https://doi.org/10.33588/rn.3211.2000159
302. Jordan, K. G. (1999). Nonconvulsive Status Epilepticus in Acute Brain Injury. Journal of Clinical Neurophysiology. https://doi.org/10.1097/00004691-199907000-00005
303. Josephs, K. A. (2011). Neuronal intranuclear inclusion disease. Neurology. https://doi.org/10.1212/wnl.0b013e3182166ead
304. Jung, J. S., Mauguı̀ere, F., Clerc-Renaud, P., Ollagnon, E., Camaret, B. M. D., & Ryvlin, P. (2007). NARP MITOCHONDRIOPATHY: AN UNUSUAL CAUSE OF PROGRESSIVE MYOCLONIC EPILEPSY. Neurology. https://doi.org/10.1212/01.wnl.0000264019.53959.10
305. Jutras, M. F., Bonnet, A. M., Czernecki, V., Corvol, J., & Vidailhet, M. (2012). Nonmotor Symptoms in Parkinson’s Disease in 2012: Relevant Clinical Aspects. Parkinson s Disease. https://doi.org/10.1155/2012/198316
306. Kahler, S. G., & Fahey, M. (2003). Metabolic disorders and mental retardation. American Journal of Medical Genetics Part C Seminars in Medical Genetics. https://doi.org/10.1002/ajmg.c.10018
307. Kaji, Y., & Hirata, K. (2012). [Depression and anxiety in Parkinson's disease].. PubMed.
308. Kaninia, S., McCarthy, R. A., Saad, Z., & Pengas, G. (2023). Young-onset dementia with Lewy Bodies presenting with apathy and alexithymia. Neurocase. https://doi.org/10.1080/13554794.2024.2354545
309. Kapoor, I., Prabhakar, H., & Mahajan, C. (2019). Postoperative Cognitive Dysfunction. Indian Journal of Critical Care Medicine. https://doi.org/10.5005/jp-journals-10071-23196
310. Karimzadeh, P. (2014). EHMTI-0298. Relationship between migraine and abnormal EEG findings in children. The Journal of Headache and Pain. https://doi.org/10.1186/1129-2377-15-s1-b16
311. Kasteleijn, D., & Szabó, C. Á. (2022). Myoclonus as a Manifestation of Reflex Seizures. Journal of Clinical Neurophysiology. https://doi.org/10.1097/wnp.0000000000000915
312. Katirji, B. (2018). Case 3. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190603434.003.0007
313. Kaufmann, H., & Biaggioni, I. (2003). Autonomic Failure in Neurodegenerative Disorders. Seminars in Neurology. https://doi.org/10.1055/s-2004-817719
314. Kaur, D., Ajinkya, S., Nabi, J., & Manzoor, A. (2012). Meningioma Masquerading as Acute Psychosis with Symptoms of Schizophrenia.
315. Kayser, M. S., Kohler, C. G., & Dalmau, J. (2010). Psychiatric Manifestations of Paraneoplastic Disorders. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2010.09101547
316. Keller, A. S., Ball, T. M., & Williams, L. M. (2018). Attention Impairments and the 'Inattention Biotype' in Major Depressive Disorder. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3235665
317. Kerchner, G. A., & Rosenbloom, M. (2014). Frontotemporal Neurocognitive Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg65
318. Keren, M., Apter, A., Mani, A., & Tyano, S. (1991). [Neuropsychiatric symptoms in systemic lupus erythematosus].. PubMed.
319. Kesler, A., & Korczyn, A. D. (2006). Visual disturbances in Parkinson's disease. Practical Neurology. https://doi.org/10.1136/jnnp.2006.088286
320. Kheder, A., Scott, C., Olpin, S. E., & Hadjivassiliou, M. (2013). Niemann–Pick type C: a potentially treatable disorder?. Practical Neurology. https://doi.org/10.1136/practneurol-2013-000525
321. Kholin, V., In, K., Kryzhanovskiy, S., Karasevich, N., Khodakovska, M., Shershanova, H., & Movchun, N. O. (2024). Cognitive disorders in Parkinson's disease. Ageing & Longevity. https://doi.org/10.47855/jal9020-2024-5-6
322. Kim, A., & Choi, S. (2019). Association between loneliness and brain volume in Aging. https://doi.org/10.26226/morressier.5d1a037257558b317a140302
323. Kim, J. S., Hong, S. B., Park, K.-W., & Lee, A. (2024). Psychotic Symptoms in Patients With Major Neurological Diseases. Journal of Clinical Neurology. https://doi.org/10.3988/jcn.2023.0501
324. Kim, M., Lee, K., Son, Y., Jeon, H., Kim, Y.-B., & Cho, Z. (2012). Increased Basal Forebrain Metabolism in Mild Cognitive Impairment: An Evidence for Brain Reserve in Incipient Dementia. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-2012-120133
325. Kim, S. H., Yu, M., & Strutt, A. M. (2019). Variably protease-sensitive prionopathy. Neurology Clinical Practice. https://doi.org/10.1212/cpj.0000000000000612
326. Kim, S., Kim, J., Heo, Y. E., Yang, H.-R., & Park, K. S. (2011). Cortical oscillopsia without nystagmus, an isolated symptom of neuromyelitis optica spectrum disorder with anti-aquaporin 4 antibody. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458511414149
327. Kimball, A. B., & Grossman, S. A. (2017). Syncope And Related Paroxysmal Spells.
328. Knight, R. (2010). 013 Differential diagnosis of rapidly progressive dementia. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2010.217554.13
329. Knupp, K. G., & Wirrell, E. (2014). Progressive myoclonic epilepsies. Neurology. https://doi.org/10.1212/wnl.0000000000000091
330. Koike, H., & Sobue, G. (2013). [Sjogren's syndrome-associated neuropathy].. PubMed.
331. Koparal, B., & Çoşar, B. (2018). Mood disorder following traumatic brain injury: a case report. The European Research Journal. https://doi.org/10.18621/eurj.434311
332. Koziorowska-Gawron, E., Koszewicz, M., Budrewićz, S., & Podemski, R. (2014). Psychogenne zaburzenia chodu — opis trzech przypadków. Polski Przegląd Neurologiczny.
333. Krebs, M., Gay, O., Martínez, G., & Amado, I. (2014). Signes neurologiques mineurs et contrôle moteur : ce qu’ils nous apprennent sur la schizophrénie, ses mécanismes et ses frontières. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2014.09.282
334. Krishna, S., Prasad, S., Goel, R., & Prasad, B. K. (2018). PARKINSON’S DISEASE- A REVIEW. Journal of Evolution of Medical and Dental Sciences. https://doi.org/10.14260/jemds/2018/295
335. Kukla, U., Łabuzek, K., Chronowska, J., Krzystanek, M., & Okopień, B. (2015). [Mental disorders in digestive system diseases - internist's and psychiatrist's insight].. PubMed.
336. Kumar, A. (2011). Prion diseases: A challenge to animal health.
337. Kundu, G. K., Akhter, A., Akhter, S., & Rhaman, M. M. (2016). Leigh syndrome: A rare mitochondrial disorder. Bangabandhu Sheikh Mujib Medical University Journal. https://doi.org/10.3329/bsmmuj.v9i2.28889
338. Kurokawa, K., NODA, K., Mimori, Y., Watanabe, C., Katayama, S., NAKAMURA, S., Sannomiya, K., Yamamoto, S., & Tahara, E. (1998). A case of pandysautonomia with associated sensory ganglionopathy. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.65.2.278
339. Kuwabara, S., & Yokota, T. (2011). Propagation: Prion-like mechanisms can explain spreading of motor neuronal death in amyotrophic lateral sclerosis?. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2011-300691
340. Labunets, І. F. (2020). NEUROPROTECTIVE EFFECTS OF THE PINEAL HORMONE MELATONIN IN ANIMALS WITH EXPERIMENTAL MODELS OF NEURODEGENERATIVE PATHOLOGY. Izdevniecība “Baltija Publishing” eBooks. https://doi.org/10.30525/978-9934-588-44-0/18
341. Laengvejkal, P., Julayanont, P., & Payne, D. (2014). Post-anoxic myoclonus. The Southwest Respiratory and Critical Care Chronicles. https://doi.org/10.12746/swrccc.v2i6.130
342. Lai, Y. (2021). Association of Cognitive Dysfunction with Cardiovascular Autonomic Nerve Abnormalities in Early Parkinson Disease. Psychology and Behavioral Science International Journal. https://doi.org/10.19080/pbsij.2021.17.555954
343. Landes, A., & Jay, W. M. (2009). Purtscher-Like Retinopathy in a Patient with Preeclampsia. Seminars in Ophthalmology. https://doi.org/10.1080/08880010903124243
344. Lang, C., & Landwehrmeyer, G. B. (2018). Die Huntington-Erkrankung. Der Klinikarzt. https://doi.org/10.1055/a-0662-3668
345. Laureno, R. (1997). Myelinolysis after Correction of Hyponatremia. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-126-1-199701010-00008
346. Lauretani, F., Saginario, A., Ceda, G. P., Galuppo, L., Ruffini, L., Nardelli, A., & Maggio, M. (2014). Treatment of the Motor and Non-Motor Symptoms in Parkinson's Disease According to Cluster Symptoms Presentation. Current Drug Targets. https://doi.org/10.2174/1389450115666140826104030
347. Lauriat, T. L., & Samson, J. (2015). Endocrine Disorders Associated with Psychological/Behavioral Problems. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780199352722.013.32
348. Lee, J. G., Park, S. W., Baek, J. H., & Kim, Y. H. (2012). Understanding the Molecular Biology in the Pathogenesis of Depression. The Korean Journal of Psychopharmacology.
349. Lees, A. J. (2002). Odd and unusual movement disorders.. PubMed. https://doi.org/10.1136/jnnp.72.suppl_1.i17
350. Lees, A. J. (2005). Atypical Parkinsonism. Humana Press eBooks. https://doi.org/10.1385/1-59259-834-x:495
351. Lennox, B. (2008). Neurocognition of depression. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780198569275.003.0021
352. Leo, R. J., Frodey, J. N., & Ruggieri, M. L. (2020). Subtle neuropsychiatric symptoms of glioblastoma multiforme misdiagnosed as depression. BMJ Case Reports. https://doi.org/10.1136/bcr-2019-233208
353. Lewis, D. W., & Berman, P. H. (1987). Progressive Weakness in Infancy and Childhood. Pediatrics in Review. https://doi.org/10.1542/pir.8.7.200
354. Li, H. (2012). Concomitant symptom and medicine related exacerbation in myasthenia gravis: how to analyse the clinical causal relationship. Zhongguo xiandai shenjing jibing zazhi.
355. Li, S., & Chen, H. (2016). Mild cognitive impairment in Parkinson's disease. DOAJ (DOAJ: Directory of Open Access Journals).
356. Liang, T.-W. (2005). Multiple pathologies in a patient with a progressive neurodegenerative syndrome. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2004.039479
357. Liepelt, I. (2007). Neuropsychologische Auffälligkeiten in der Frühphase des Morbus Parkinson. Aktuelle Neurologie. https://doi.org/10.1055/s-2007-987454
358. Lijo.J, J., James, P. M., & Sherief.S, H. (2020). Case Report on Young Onset Parkinson's Disease. International Journal of Research.
359. Lim, J., Kwek, S. K. D., How, C., & Chan, D. (2020). A clinical approach to encephalopathy in children. Singapore Medical Journal. https://doi.org/10.11622/smedj.2020176
360. Limongelli, G., D‘Alessandro, R., Maddaloni, V., Rea, A., Sárközy, A., & McKenna, W. J. (2013). Skeletal muscle involvement in cardiomyopathies. Journal of Cardiovascular Medicine. https://doi.org/10.2459/jcm.0b013e3283641c69
361. Littner, M. R., Hirshkowitz, M., Kramer, M., Kapen, S., Anderson, W. M., Bailey, D. R., Berry, R. B., Davila, D., Johnson, S., Kushida, C. A., Loube, D. I., Wise, M. S., & Woodson, B. T. (2003). Practice Parameters for Using Polysomnography to Evaluate Insomnia: An Update. SLEEP. https://doi.org/10.1093/sleep/26.6.754
362. Liu, J., Niu, Y., Tong, L., Song, S., Li, Y., Sun, R., & Li, B. (2018). Recent advances in diagnosis and treatment of PEHO syndrome. https://doi.org/10.3760/cma.j.issn.1008-1372.2018.09.004
363. Lizbeth, V. C., Amiel, T. R., Rafael, G. P. J., Gerardo, M. M., Rebeca, T. C. M., Porfirio, C. C., Jorge, M. D., Genaro, C. A., & Luis, G. H. (2019). Enfermedad de Parkinson más allá de lo motor. eNeurobiología.
364. Lo, S. E., & Frucht, S. J. (2012). Myoclonus. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-120-2_5
365. Louis, E. D., & Bennett, D. A. (2007). Mild Parkinsonian signs: An overview of an emerging concept. Movement Disorders. https://doi.org/10.1002/mds.21433
366. Low, P. A. (1998). Autonomic neuropathies. Current Opinion in Neurology. https://doi.org/10.1097/00019052-199810000-00016
367. Lozsádi, D. A. (2012). Myoclonus: a pragmatic approach. Practical Neurology. https://doi.org/10.1136/practneurol-2011-000107
368. Lv-hu, C. (2013). The Research Progress of Relationship between Migraine and Stroke. Medical Recapitulate.
369. Lyketsos, C. G., López, O. L., Jones, B. N., Fitzpatrick, A. L., Breitner, J. C., & DeKosky, S. T. (2002). Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment. JAMA. https://doi.org/10.1001/jama.288.12.1475
370. Lyons, K. E., & Pahwa, R. (2011). The impact and management of nonmotor symptoms of Parkinson's disease.. PubMed.
371. Maas, J. W. (1979). Biochemistry of the Affective Disorders. Hospital Practice. https://doi.org/10.1080/21548331.1979.11707547
372. Magalhaes, É., Polito, A., Polito, A., & Sharshar, T. (2014). Sepsis-Associated Encephalopathy. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199653461.003.0032
373. Magner, M. (2019). Clinical Manifestation of Mitochondrial Disorders in Childhood. CRC Press eBooks. https://doi.org/10.1201/9780429443336-21
374. Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., & Tamburin, S. (2016). Pathophysiology of Motor Dysfunction in Parkinson’s Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinson s Disease. https://doi.org/10.1155/2016/9832839
375. Majhi, V., Paul, S., Saha, G., & Verma, J. K. (2020). Sensor based Detection of Parkinson’s Disease Motor Symptoms. 2021 International Conference on Computational Performance Evaluation (ComPE). https://doi.org/10.1109/compe49325.2020.9200051
376. Malhotra, A., & Monu, J. U. V. (2010). Neuropathic Osteoarthropathy. Contemporary Diagnostic Radiology. https://doi.org/10.1097/01.cdr.0000369482.23981.d9
377. Maltseva, L., Lisnycha, V., Kobelatskyy, Y., & Kazimirova, N. (2021). Вплив додаткової нейропротекції Гліатиліном на перебіг септичного процесу і вираженість енцефалопатії в структурі синдрому поліорганної недостатності. EMERGENCY MEDICINE. https://doi.org/10.22141/2224-0586.17.2.2021.230634
378. Manquillo, A., Martinez, J., Paradinas, F., Sáez, J., Quintana, P. R., Revilla, C., López-Esteban, P., & Martínez-Galán, J. (1999). Trastorno de conducta durante el sueño MOR. Dos casos clínicos. Revista de Neurología. https://doi.org/10.33588/rn.2812.98916
379. Marchettini, P., Lacerenza, M., Mauri, E., & Marangoni, C. (2006). Painful Peripheral Neuropathies. Current Neuropharmacology. https://doi.org/10.2174/157015906778019536
380. Margari, L., Legrottaglie, A. R., Craig, F., Petruzzelli, M. G., Procoli, U., & Dicuonzo, F. (2012). Ophthalmoplegic migraine: Migraine or oculomotor neuropathy?. Cephalalgia. https://doi.org/10.1177/0333102412463493
381. Marin, R. S., & Wilkosz, P. A. (2005). Disorders of Diminished Motivation. Journal of Head Trauma Rehabilitation. https://doi.org/10.1097/00001199-200507000-00009
382. Marrero, D. H., Pestano, M. M. A., Acosta, B. A., & Miranda, J. L. D. (2020). La ptosis no orgánica: a propósito de un trastorno.
383. Marrero, D. H., Pestano, M. M. A., Acosta, B. A., & Miranda, J. L. D. (2021). La ptosis no orgánica; a propósito de un trastorno conversivo.
384. Marsden, C. D. (1984). Which Motor Disorder in Parkinson's Disease Indicates the True Motor Function of the Basal Ganglia?. Novartis Foundation symposium. https://doi.org/10.1002/9780470720882.ch12
385. Martell, M. A. L. (2019). Marco teórico de la presente investigación. Revista Cubana de Alimentación y Nutrición.
386. Martinović, A.-M., & Krhen, A. L. (2019). Neurogeno mucanje. Logopedija. https://doi.org/10.31299/log.9.1.3
387. Martín, E. S. S., Juanes, J., Montero, R., & Aguiar, C. S. (2012). Demencia frontotemporal asociada al cromosoma 17 y otros síndromes parkinsonianos asociados a demencia. Revista de Neurología. https://doi.org/10.33588/rn.54s04.2012520
388. Martínez, M. M. M., Pérez, N. M., Berdejo, S. D., Palacian, N. S., & Peniche, N. G. (2021). Síndrome de Moebius.. Revista Sanitaria de Investigación.
389. Martínez-Pérez, R., Paredes, I., Munárriz, P. M., Paredes, B., & Alén, J. (2014). Encefalopatía crónica postraumática: aquella gran desconocida. Neurología. https://doi.org/10.1016/j.nrl.2014.08.009
390. Mason, M., Marotta, D., & Kesserwani, H. (2021). Isolated Double-Positive Optic Neuritis: A Case of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody Seropositivity. Cureus. https://doi.org/10.7759/cureus.15389
391. Masse, C., Chopard, G., Bennabi, D., Haffen, É., & Vandel, P. (2021). Cognitive functions in late life depression. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2021.0939
392. Mathias, C. J., & Low, D. A. (2020). Diseases of the autonomic nervous system. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0603
393. Mathis, S., Tazir, M., & Vallat, J. (2014). Other hereditary neuropathies. https://doi.org/10.1002/9781118618424.ch21
394. Mayne, K., White, J. A., McMurran, C. E., Rivera, F. J., & Fuente, A. G. D. L. (2020). Aging and Neurodegenerative Disease: Is the Adaptive Immune System a Friend or Foe?. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2020.572090
395. McCracken, L. M., Hindle, J. V., Bogosian, A., Robertson, N. P., Meco, G., & Hennig, E. M. (2020). Advances in Peripheral Neuropathy in Parkinson’s Disease.
396. McDougall, G. J., Vaughan, P. W., Acee, T. W., & Becker, H. (2007). Memory performance and mild cognitive impairment in Black and White community elders.. Ethnicity & Disease.
397. McGirr, A., Nathan, S., Ghahremani, M., Gill, S., Smith, E. E., & Ismail, Z. (2022). Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms. Neurology. https://doi.org/10.1212/wnl.0000000000200256
398. McGuigan, C., O’Connell, K., McGovern, E., & McGurgan, I. (2019). Medical pathologies of the spinal cord. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746706.003.0059
399. McIntyre, R. S., Danielle, S., & Soczynska, J. K. (2014). Differentiating cognitive dysfunction from other dimensions of psychopathology in major depressive disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199688807.003.0005
400. McLeod, J. G. (1993). Autonomic Dysfunction in Peripheral Nerve Disease. Journal of Clinical Neurophysiology. https://doi.org/10.1097/00004691-199301000-00006
401. McLeod, J. G., & Tuck, R. R. (1987). Disorders of the autonomic nervous system: Part 1. Pathophysiology and clinical features. Annals of Neurology. https://doi.org/10.1002/ana.410210502
402. McMurtray, A., Tseng, B., Diaz, N., Chung, J., Mehta, B., & Saito, E. (2014). Acute Psychosis Associated with Subcortical Stroke: Comparison between Basal Ganglia and Mid-Brain Lesions. Case Reports in Neurological Medicine. https://doi.org/10.1155/2014/428425
403. Meinck, H., & Ringleb, P. (2007). B 2.9.1 Vorbemerkung.
404. Menculini, G., Chipi, E., Paoletti, F. P., Gaetani, L., Nigro, P., Simoni, S., Mancini, A., Tambasco, N., Filippo, M. D., Tortorella, A., & Parnetti, L. (2021). Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22094440
405. Mendez, M. F. (2001). Emergent Neuroleptic Hypersensitivity as a Herald of Presenile Dementia. Journal of Neuropsychiatry. https://doi.org/10.1176/appi.neuropsych.13.3.347
406. Meriç, C., Pirdoğan, E., Toker, Ö. G., Tekın, A., Bakim, B., & Çelik, S. (2014). [Mania with psychotic feature induced by the use of pramipexole in Parkinson's disease: a case report].. PubMed.
407. Meyding‐Lamadé, U., & Craemer, E. M. (2020). Meningitis/Meningoenzephalitis – ein Chamäleon in der Medizin. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/a-1117-6978
408. Miklya, I., Göltl, P., Hafenscher, F., & Pencz, N. (2007). The Role of PARKIN in Parkinson’s Disease. CRC Press eBooks. https://doi.org/10.3109/9781420019223-17
409. Millin, M. G., Shah, S. M., & Wright, D. G. (2003). Nontraumatic Spinal Cord Emergencies. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511547256.027
410. Mirali, H., Aichouni, N., Berkhli, H., Nasri, S., Kamaoui, I., Serji, B., & Skiker, I. (2021). Gayet Wernicke encephalopathy after cephalic pancreaticoduodenectomy. Authorea (Authorea). https://doi.org/10.22541/au.161913610.06234974/v1
411. Mirmiran, M., & Swaab, D. F. (1987). Influence of Drugs on Brain Neurotransmitters and Behavioral States during Development1. Developmental Pharmacology and Therapeutics. https://doi.org/10.1159/000457767
412. Mishra, T., Kamble, N., Bhattacharya, A., Yadav, R., Srinivas, D., & Pal, P. K. (2024). Impact of Deep Brain Stimulation on Non-Motor Symptoms in Parkinson’s Disease. Journal of Movement Disorders. https://doi.org/10.14802/jmd.23247
413. Mizuno, T., Matsumoto, H., Mita, K., Kogauchi, S., Kiyono, Y., Kosaka, H., & Omata, N. (2019). Psychosis is an extension of mood swings from the perspective of neuronal plasticity impairments. Medical Hypotheses. https://doi.org/10.1016/j.mehy.2019.02.001
414. MM, B., Islam, S., Nh, S., Rahman, M., & Bari, M. (2016). None. MOJ Orthopedics & Rheumatology. https://doi.org/10.15406/mojor.4.1
415. Mochizuki, H., & Ugawa, Y. (2019). Atactic Symptoms Based on the Cerebellar Function. The Japanese Journal of Rehabilitation Medicine. https://doi.org/10.2490/jjrmc.56.88
416. Mograbi, D. C., & Morris, R. G. (2013). Implicit awareness in anosognosia: Clinical observations, experimental evidence, and theoretical implications. Cognitive Neuroscience. https://doi.org/10.1080/17588928.2013.833899
417. Mohsin, K. A. H. (2010). Autonomní nervový systém u pacientů s neurologickým onemocněním: dětská mozková obrna.
418. Moin, A., Prasad, B. N. S., Ramaswamy, S., & Nalloor, S. (2022). Neurosarcoidosis Camouflaging as Partial Miller: Fisher Syndrome. Indian Journal of Rheumatology. https://doi.org/10.4103/injr.injr_148_22
419. Mollenhauer, B., & Weintraub, D. (2017). The depressed brain in Parkinson's disease: Implications for an inflammatory biomarker. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1700737114
420. Moore, D. P., & Puri, B. K. (2012). Textbook of Clinical Neuropsychiatry and Behavioral Neuroscience 3E.
421. Morrens, M., Hulstijn, W., & Sabbe, B. (2008). [Psychomotor symptoms in schizophrenia: the importance of a forgotten syndrome].. Tijdschrift voor psychiatrie.
422. Morris, J. G., & McManus, D. Q. (1991). The neurology of aging: normal versus pathologic change.. PubMed.
423. Moryś, J. M., Jeżewska, M., & Korzeniewski, K. (2015). Neuropsychiatric manifestations of some tropical diseases. International Maritime Health. https://doi.org/10.5603/imh.2015.0009
424. Moshirfar, M., Benstead, E. E., Sorrentino, P. M., & Tripathy, K. (2019). Ocular Neuropathic Pain. StatPearls.
425. Moshé, S. L., Tuchman, R. F., & Rapin, I. (2005). [Neurodevelopmental disorders and epilepsy].. PubMed.
426. Mostoufizadeh, S., Souri, M., & Sèze, D. (2012). A Case of Paraneoplastic Demyelinating Motor Polyneuropathy. Case Reports in Neurology. https://doi.org/10.1159/000338296
427. Mukherjee, D., Bhattacharyya, D., Pandit, A., & Dubey, S. (2022). Higher order visual dysfunction and myoclonic-atonic seizure: an atypical presentation of CLN6 neuronal ceroid lipofuscinosis. BMJ Case Reports. https://doi.org/10.1136/bcr-2021-247790
428. Munawar, M., Iftikhar, P. M., Khan, J. A., Syed, N. A., & Syed, T. A. (2019). A Case Report of Seronegative Limbic Encephalitis. Cureus. https://doi.org/10.7759/cureus.4681
429. Munjal, S., Pahlajani, S., Baxi, A., & Ferrando, S. J. (2016). Delayed Diagnosis of Glioblastoma Multiforme Presenting With Atypical Psychiatric Symptoms. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.16l01972
430. Munsat, T. L. (1977). Serotonin and Myoclonic Seizures. New England Journal of Medicine. https://doi.org/10.1056/nejm197701132960210
431. Murphy, R. A., O’Donoghue, S., Counihan, T. J., McDonald, C., Calabresi, P. A., Ahmed, M. A., Kaplin, A., & Hallahan, B. (2017). Neuropsychiatric syndromes of multiple sclerosis. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2016-315367
432. Murueta‐Goyena, A., Andikoetxea, A., Gómez‐Esteban, J. C., & Gabilondo, I. (2019). Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson’s Disease. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2019.01294
433. Muzerengi, S., Lewis, H. M., Edwards, M. J., Kipps, E., Bahl, A., Martínez‐Martín, P., & Chaudhuri, К. R. (2006). Non-motor symptoms in Parkinson's disease: an underdiagnosed problem. Aging Health. https://doi.org/10.2217/1745509x.2.6.967
434. Møller, A. R. (2001). Symptoms and signs caused by neural plasticity. Neurological Research. https://doi.org/10.1179/016164101101199009
435. Nagao, R., Mizutani, Y., Shima, S., Ueda, A., Ito, M., Yoshimoto, J., & Watanabe, H. (2023). Correlations between serotonin impairments and clinical indices in multiple system atrophy. European Journal of Neurology. https://doi.org/10.1111/ene.16158
436. Najjar, S., Pearlman, D. M., Devinsky, O., Najjar, A., & Zagzag, D. (2013). Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. Journal of Neuroinflammation. https://doi.org/10.1186/1742-2094-10-142
437. Nakamura, S. (2022). Integrated pathophysiology of schizophrenia, major depression, and bipolar disorder as monoamine axon disorder. Frontiers in Bioscience-Scholar. https://doi.org/10.31083/j.fbs1401004
438. Narayanan, N. S., Rodnitzky, R. L., & Ebadi, M. (2013). Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease. Reviews in the Neurosciences. https://doi.org/10.1515/revneuro-2013-0004
439. NASCIMENTO, R. T. L., LOPES, C. B., COTTA, D. D. S., ALENCAR, N. L. O. R. D., Valadão, A. F., & Motta, P. G. D. (2015). NEUROPATIA DIABÉTICA DOLOROSA - ASPECTOS CLÍNICOS, DIAGNÓSTICO E TRATAMENTO: UMA REVISÃO DE LITERATURA. Revista Uningá. https://doi.org/10.46311/2318-0579.43.euj1215
440. Nath, B. D., Debnath, D., Pervin, R., & Hossain, M. A. (2020). Role of Environmental Toxicants and Inflammation in Parkinson’s Disease. CRC Press eBooks. https://doi.org/10.1201/9780429319310-6
441. Neary, D., & Snowden, J. S. (2002). Sorting out the Dementias. Practical Neurology. https://doi.org/10.1046/j.1474-7766.2002.00104.x
442. Nelson, A. J., & Klassen, B. T. (2015). Hypokinetic Movement Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190244927.003.0025
443. Nicoletti, G. (2010). Sporadic Parkinsonism. BMC Geriatrics. https://doi.org/10.1186/1471-2318-10-s1-l40
444. Nikolić, S., Vukomanović, J., Milovanović, D., Perović, G., & Jevtić, M. (2010). An axis trunk hypotonia in infants and kinezitherapy.
445. Nobels-Janssen, E., Kort, F. A. D., Linn, F., & Verrips, A. (2021). [Awakening ptosis].. PubMed.
446. Nunes, T., Fragata, I., Ribeiro, F., Palma, T., Marôco, J., Cannas, J., Secca, M. F., Menezes, C. M., Carmo, I. D., Cunha, G., Castelo‐Branco, M., Guerreiro, M., & Mendonça, A. D. (2010). The Outcome of Elderly Patients with Cognitive Complaints but Normal Neuropsychological Tests. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-2010-1210
447. Nyland, H., Glad, S. B., & Myhr, K. (2006). Benign multiple sclerosis. Acta Neurologica Scandinavica. https://doi.org/10.1111/j.1600-0404.2006.00617.x
448. Nytrová, P., Dušánková, J. B., & Nawka, A. (2017). Neuropsychiatrické poruchy u roztroušené sklerózy. Medicína pro praxi.
449. Nzuzi, L. D. (2021). News on neuropalaria: broca's aphasia complicating encephalitis acute malaria, approach neuroadapted therapeutics: Place of citicholine and neuroregulators in prevention, reduction of sequelae neurological and morbidity and mortality.
450. Oakley, D. A., Ward, N., Halligan, P. W., & Frackowiak, R. S. J. (2003). Differential brain activations for malingered and subjectively ‘real’ paralysis. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198515548.003.0021
451. Obeid, T., Bahemuka, M., Shemena, A. R., Panayiotopoulos, C. P., Al-Aska, A. K., & Daif, A. K. (1988). Neurological syndromes of brucellosis.. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.51.8.1017
452. Oertel, W. H., Vadász, D., Ries, V., Mayer, G., Eggert, K., Krenzer, M., Unger, M. M., Höglinger, G. U., Mollenhauer, B., Sixel-Döring, F., Trenkwalder, C., & Depboylu, C. (2013). Prodromale Marker der Parkinson-Krankheit. Aktuelle Neurologie. https://doi.org/10.1055/s-0033-1355379
453. Ogata, T., Sakakibara, R., Tateno, F., Tsuyusaki, Y., Tateno, H., Aiba, Y., Kishi, M., Inaoka, T., Terada, H., Doi, H., & Suzuki, Y. (2016). Mild Cognitive Impairment as the Initial Manifestation of Progressive Supranuclear Palsy. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.14001
454. Ohno, K. (2010). [Continuous clinical management of patients with neurofibromatosis type 1].. PubMed.
455. Operto, F. F., Pastorino, G. M. G., Padovano, C., Scuoppo, C., Vivenzio, V., & Coppola, G. (2020). Psychogenic Seizures in Adolescents: An “Evergreen” Diagnostic Challenge. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.18662/brain/11.3sup1/131
456. Ornelas, L. E. F. (2016). Modulating the aggregation of alpha-synuclein and prion protein with small molecules.. https://doi.org/10.53846/goediss-5964
457. Orrell, R. W. (2011). GPs have key role in managing motor neurone disease.. PubMed.
458. Orsini, A., Valetto, A., Bertini, V., Esposito, M., Carli, N., Minassian, B. A., Bonuccelli, A., Peroni, D., Michelucci, R., & Striano, P. (2019). The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy. Seizure. https://doi.org/10.1016/j.seizure.2019.08.012
459. Ortiz, G. (2006). Trastornos neurogenéticos y neurometabólicos paroxísticos. Revista de Neurología. https://doi.org/10.33588/rn.42s03.2006027
460. Ortiz, Y. D. L. C. R., García, M. D. L. C. C., Castillo, M. C., Rodríguez, S. T., & García, A. O. G. (2012). Síndrome de Guillain Barré en edad pediátrica. Presentación atípica.. Gaceta Médica Espirituana.
461. Ouvrier, R., & Menezes, M. P. (2014). Neuroaxonal dystrophy. https://doi.org/10.1002/9781118618424.ch19
462. Ovsiew, F. (1993). Neuropsychiatric sequelae of brain injury of vascular and traumatic origin. Current Opinion in Psychiatry. https://doi.org/10.1097/00001504-199302000-00020
463. Pacchetti, C., Cristina, S., Mancini, F., Fundarò, C., Corengia, E., Martignoni, E., & Nappi, G. (2000). Sintomi non motori nella malattia di Parkinson: Procedure per la diagnosi, la terapia e la riabilitazione.
464. Paine, M. (2005). Dealing with dizziness. Australian Prescriber. https://doi.org/10.18773/austprescr.2005.075
465. Painous, C., & Martı́, M. J. (2020). &lt;p&gt;Cognitive Impairment in Parkinson’s Disease: What We Know so Far&lt;/p&gt;. Research and Reviews in Parkinsonism. https://doi.org/10.2147/jprls.s263041
466. Palma, G. D. (1985). Paraneoplastic syndromes of the nervous system.. PubMed.
467. Palmer, S. C., Zwieten, A. V., Saglimbene, V., Ruospo, M., & Strippoli, G. F. (2022). Neurocognitive Disorders. https://doi.org/10.1002/9781119105954.ch75
468. Panicker, J. N., Mammachan, R., & Jayakumar, R. V. (2001). Primary neuroleptospirosis. Postgraduate Medical Journal. https://doi.org/10.1136/pmj.77.911.589
469. Pant, S. B., Upadhyaya, S., Dhungana, S., Tulachan, P., Chapagai, M., & Ojha, S. P. (2020). Neuropsychiatric manifestations in General Paralysis of Insane (GPI).. Kathmandu University Medical Journal.
470. Papmeyer, M., Sussmann, J. E., Hall, J., McKirdy, J., Peel, A. J., MacDonald, A. J., Lawrie, S. M., Whalley, H. C., & McIntosh, A. M. (2015). Neurocognition in individuals at high familial risk of mood disorders with or without subsequent onset of depression. Psychological Medicine. https://doi.org/10.1017/s0033291715001324
471. Parate, T., Tony, K. S., Bhiwgade, R. D., & Pathan, F. (2022). Neuropsychiatric Manifestation of Acute Intermittent Porphyria: A Case Report. Vidarbha Journal of Internal Medicine. https://doi.org/10.25259/vjim_10_2021
472. Pardo, R. (1997). Nuevos y viejos anticonvulsivantes. Revista de la Facultad de Medicina.
473. Park, H. S. (2012). A Case of Motor Neuron Disease Presenting as Dyspnea in the Emergency Department. Korean Journal of Family Medicine. https://doi.org/10.4082/kjfm.2012.33.2.110
474. Parker, R. S. (2012). Chronic Posttraumatic Disorders of Consciousness. CRC Press eBooks. https://doi.org/10.1201/b10562-14
475. Parkes, J. D., Jenner, P., Rushton, D. N., & Marsden, C. D. (1987). Treatment of Disorders Involving the Autonomic Nervous System. Treatment in clinical medicine. https://doi.org/10.1007/978-1-4471-3140-3_10
476. Pascual, A., Salvador, A., Gil, R., & Láinez, M. J. A. (2005). Posttraumatic Migraine Secondary to Organic Lesions. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198565901.003.0032
477. Patel, J. P., Edwards, A. D., & Azzopardi, D. (1997). Prevention of acquired neurological impairment in the perinatal period. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.63.2008.34s
478. Paul, M., Somarajan, A., Ka, K., & Krishnapriyam, S. (2007). Ataxic form of central pontine myelinolysis. Annals of Indian Academy of Neurology. https://doi.org/10.4103/0972-2327.33220
479. Pauls, K., & Timmermann, L. (2014). Pathogenesis of movement disorders: basic neuroanatomy and pathophysiology. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139175845.003
480. Paulson, G. W. (1985). Early Alzheimer's disease or dementia from another cause?. Postgraduate Medicine. https://doi.org/10.1080/00325481.1985.11699069
481. Pavlović, D., & Pavlović, A. (2009). Mild cognitive impairment. Srpski arhiv za celokupno lekarstvo. https://doi.org/10.2298/sarh0908434p
482. Pawar, J. A., & Nere, N. P. (2015). Misdiagnosed schizophrenia be Megaloblastic.
483. Peixinho, A. T., Azevedo, A., & Simões, R. M. (2006). Alterações neuropsiquiátricas da doença de Parkinson. https://doi.org/10.25752/psi.6037
484. Penubarthi, S., Miryala, R., Vatte, V. R., & Kandrakonda, S. (2022). Neuropsychological impairments in a young-onset Marchiafava–Bignami disease with alcohol-dependence syndrome. Telangana Journal of Psychiatry. https://doi.org/10.4103/tjp.tjp_31_22
485. Peralta, C. (2013). [Neuropsychiatric non motor symptoms of Parkinson's disease].. PubMed.
486. Peretti, C.-S., Ferreri, F., & Crucis, B. (2009). Troubles cognitifs dans la dépression. La Lettre du psychiatre.
487. Peters, M. (2005). Apraxia. Encyclopedia of Cognitive Science. https://doi.org/10.1002/0470018860.s00322
488. Peterson, H. W., & Martin, M. (1973). Organic Disease Presenting as a Psychiatric Syndrome. Postgraduate Medicine. https://doi.org/10.1080/00325481.1973.11713534
489. Peterson, L. G., & O’Shanick, G. J. (1985). Psychiatric symptoms in endocrine diseases. Postgraduate Medicine. https://doi.org/10.1080/00325481.1985.11698963
490. Phillips, L., Chhabra, A., & Trivedi, J. (2015). Hereditary and Acquired Polyneuropathy Conditions of the Peripheral Nerves: Clinical Considerations and MR Neurography Imaging. Seminars in Musculoskeletal Radiology. https://doi.org/10.1055/s-0035-1545076
491. Piedimonte, F., & Acosta, T. (2018). Núcleo Pedúnculo Pontino. NeuroTarget. https://doi.org/10.47924/neurotarget2018111
492. Platt, S. R., & Shelton, G. D. (2013). Exercise intolerance and collapse. British Small Animal Veterinary Association eBooks. https://doi.org/10.22233/9781910443125.18
493. Poewe, W. (2006). The need for neuroprotective therapies in Parkinson’s disease. Neurology. https://doi.org/10.1212/wnl.66.10_suppl_4.s2
494. Polster, T., Jamra, R. A., Sticht, H., & Woermann, F. G. (2021). Pathogenic Variants in SCN2A Are Associated with Severe Developmental and Epileptic Encephalopathy with Bilateral Polymicrogyria and Incomplete Opercularization. Neuropediatrics. https://doi.org/10.1055/s-0041-1739618
495. Ponnala, A. K., Paul, B., Swaminadhan, D., & Martin, T. M. (2024). Prophylactic and Therapeutic Effects of Progesterone on the Preterm Brain Injury Rat Model. Cureus. https://doi.org/10.7759/cureus.70105
496. Possin, K. L., & Kaufer, D. (2010). Parkinsonian Dementias. CONTINUUM Lifelong Learning in Neurology. https://doi.org/10.1212/01.con.0000368212.86835.a8
497. Poulose, S. M., Carey, A. N., & Shukitt‐Hale, B. (2012). Improving brain signaling in aging: could berries be the answer?. Expert Review of Neurotherapeutics. https://doi.org/10.1586/ern.12.86
498. Pr, D. (1975). Headaches in children.. PubMed.
499. Praag, H. M. V., & Korf, J. (1975). Central Monoamine Deficiency in Depressions: Causative or Secondary Phenomenon?<sup>*</sup>. Pharmacopsychiatry. https://doi.org/10.1055/s-0028-1094463
500. Pratibha, S. (2010). Etiology of Late Onset Seizures.
501. Praško, J., Doubek, P., Divéky, T., Grambal, A., Grambalová, Z., Herman, E., Hovorka, J., Kamarádová, D., Kovaczová, A., Látalová, K., & Šilhán, P. (2010). Úzkostné poruchy v neurologii. Neurologie pro praxi.
502. Presečki, P., & Mimica, N. (2007). Involuntary emotional expression disorder - new/old disease in psychiatry and neurology.. PubMed.
503. Presečki, P., Filipčić, I., Arbanas, G., & Mimica, N. (2014). Neurocognitive disorders in DSM-5.
504. Prichep, L., John, E. R., Fridman, J., & Easton, P. A. (1988). Neurometrics: Computer-Assisted Differential Diagnosis of Brain Dysfunctions. Science. https://doi.org/10.1126/science.3336779
505. Pringsheim, T., Chen, R., & Lang, A. E. (2006). Psychogenic motor disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198525769.003.0022
506. Provini, F., Lombardi, C., & Lugaresi, E. (2005). Insomnia in Neurological Diseases. Seminars in Neurology. https://doi.org/10.1055/s-2005-867074
507. Provini, F., Lombardi, C., & Lugaresi, E. (2007). Insomnia in Neurological Diseases and Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-042-7_16
508. Prudenzano, M. P., Puca, F. M., Savarese, M., Genco, S., & Specchio, L. M. (1997). Stress, mood disorders and memory in headache.. PubMed.
509. Pérez, J. E. T., Martí, A. S., Aramburu, M. H., Bottan, J. S., & Burneo, J. G. (2020). Epilepsia del lóbulo temporal plus: revisión. Revista de Neurología. https://doi.org/10.33588/rn.7106.2020339
510. Qayyum, A., Varanese, S., Perfetti, B., Di, A., Suzuki, K., Miyamoto, T., Miyamoto, M., Iwanami, M., Hirata, K., Fernandez, R. R., António, J., Casado, M., Lieu, C. A., Shivkumar, V., Gilmour, T. P., Venkiteswaran, K., Nolt, M. J., Deogaonkar, M., Subramanian, T., ... Ribarič, S. (2011). Symptoms of Parkinson's Disease. InTech eBooks. https://doi.org/10.5772/953
511. Rabbani, S. A., Khaled, B., Khaled, H., Sharma, S., Pottoo, F. H., & Mahtab, A. (2023). Neurochemical Alterations in Parkinson's Disease. CRC Press eBooks. https://doi.org/10.1201/9780429265198-9
512. Rajagopalan, J., & Rangaswamy, P. (2015). Conversion disorder in childhood presenting as movement disorder with severe injuries. Journal of Pediatric Neurology. https://doi.org/10.3233/jpn-120575
513. Rajbhandari, S., Powell, T., Davies-Jones, G., & Ward, J. D. (1998). Central pontine myelinolysis and ataxia: an unusual manifestation of hypoglycaemia. Diabetic Medicine. https://doi.org/10.1002/(sici)1096-9136(199803)15:3<259::aid-dia548>3.0.co;2-j
514. Rajbhandari, S., Powell, T., Davies‐Jones, G., & Ward, J. (1998). Central pontine myelinolysis and ataxia: an unusual manifestation of hypoglycaemia. Diabetic Medicine. https://doi.org/10.1002/(sici)1096-9136(199803)15:3<259::aid-dia548>3.3.co;2-a
515. Rajput, R., Kaur, R., Chadha, R., Mani, S., Rachana, R., Kaur, H., & Singh, M. (2022). The Aging Brain. IGI Global eBooks. https://doi.org/10.4018/978-1-6684-5295-0.ch008
516. Ralot, T. K., Jatav, V., Karimji, S., & Sharma, V. (2024). Syringomyelia Mimicking as Bibrachial Variant of Motor Neuron Disease. Journal of the Association of Physicians of India. https://doi.org/10.59556/japi.72.0721
517. Ratai, E., Caruso, P. A., & Eichler, F. (2012). Advances in MR Imaging of Leukodystrophies. InTech eBooks. https://doi.org/10.5772/25151
518. Ravenhill, S. M., Evans, A., & Crewther, S. G. (2023). Escalating Bi-Directional Feedback Loops between Proinflammatory Microglia and Mitochondria in Ageing and Post-Diagnosis of Parkinson’s Disease. Antioxidants. https://doi.org/10.3390/antiox12051117
519. Ravina, B., Marder, K., Fernandez, H. H., Friedman, J. H., McDonald, W. M., Murphy, D., Aarsland, D., Babcock, D., Cummings, J., Endicott, J., Factor, S. A., Galpern, W. R., Lees, A. J., Marsh, L., Stacy, M., Gwinn, K., Voon, V., & Goetz, C. G. (2007). Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group. Movement Disorders. https://doi.org/10.1002/mds.21382
520. Reading, P. (2010). Sleep disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.240503_update_001
521. Reich, S. G. (2006). Psychogenic Disorders. Seminars in Neurology. https://doi.org/10.1055/s-2006-945514
522. Reijnders, M. R., Leventer, R. J., Lee, B. H., Baralle, D., Selber, P., Paciorkowski, A. R., & Hunt, D. (2017). PURA-Related Neurodevelopmental Disorders. University of Washington, Seattle eBooks.
523. Reis, H. J., Oliveira, A., Mukhamedyarov, M. A., Rizvanov, A. A., Yalvaç, M. E., Teixeira, A. L., Janka, Z., Hussain, A., Vieira, L. B., & Palotás, A. (2014). Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient. Current Molecular Medicine. https://doi.org/10.2174/1566524014666140603114655
524. Remberk, B. (2017). Clinical significance of psychotic-like experiences in children and adolescents.. Psychiatria Polska. https://doi.org/10.12740/pp/63894
525. Reuck, J. D. (2012). Cognitive Impairment and Seizures in Patients with Lacunar Strokes. European Neurological Review. https://doi.org/10.17925/enr.2013.08.01.27
526. Revuelta, G. J., Kumaraswamy, G. K., & Lippa, C. F. (2015). Pathological correlates of dementia in Parkinson’s disease. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199681648.003.0015
527. Ribeiro, B. M. M., Menezes, A., Souza, G. C. D., Vale, M., & Macêdo, D. S. (2014). NDD. 04. Progressive microglial activation in the striatum in rats submitted to a neurodevelopmental model of schizophrenia: reversal by clozapine. Blucher Neuroscience Proceedings. https://doi.org/10.5151/isnm-sine28
528. Rich, J. (2001). Degenerative Central Nervous System (CNS) Disease. Pediatrics in Review. https://doi.org/10.1542/pir.22.5.175
529. Riederer, P., & Gerlach, M. (1993). The Pathophysiological Basis of Parkinson’s Disease. Milestones in drug therapy. https://doi.org/10.1007/978-3-0348-6348-3_2
530. Rigaud, J., Lheureux, P., & Sauder, P. (2006). Prise en charge symptomatique : neurologique, respiratoire, hémodynamique et hépatique des intoxications graves par médicaments et substances illicites. Réanimation. https://doi.org/10.1016/j.reaurg.2006.08.002
531. Riggio, S., Filipovic‐Jewell, Z., & Thakur, D. S. (2016). Neuropsychiatric Illnesses. https://doi.org/10.1002/9781118654231.ch19
532. Rinn, W. E. (1988). Mental Decline in Normal Aging: A Review. Journal of Geriatric Psychiatry and Neurology. https://doi.org/10.1177/089198878800100304
533. Rison, R. A., & Beydoun, S. R. (2016). Differentiating Multifocal Motor Neuropathy from Entrapment Neuropathy—A Diagnostic Challenge. touchREVIEWS in Neurology. https://doi.org/10.17925/usn.2016.12.01.17
534. Riva, A., D’Onofrio, G., Ferlazzo, E., Pascarella, A., Pasini, E., Franceschetti, S., Panzica, F., Canafoglia, L., Vignoli, A., Coppola, A., Badioni, V., Beccaria, F., Labate, A., Gambardella, A., Romeo, A., Capovilla, G., Michelucci, R., Striano, P., & Belcastro, V. (2024). Myoclonus: Differential diagnosis and current management. Epilepsia Open. https://doi.org/10.1002/epi4.12917
535. Rizvi, A. H., & Karetzky, M. S. (1993). Action myoclonus after cerebral anoxia.. PubMed.
536. Robinson, R. G. (2006). Biological markers. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544231.021
537. Rodner, C. M., Tinsley, B. A., & O’Malley, M. (2013). Pronator Syndrome and Anterior Interosseous Nerve Syndrome. Journal of the American Academy of Orthopaedic Surgeons. https://doi.org/10.5435/00124635-201305000-00003
538. Rodner, C. M., Tinsley, B. A., & O’Malley, M. (2013). Pronator Syndrome and Anterior Interosseous Nerve Syndrome. Journal of the American Academy of Orthopaedic Surgeons. https://doi.org/10.5435/jaaos-21-05-268
539. Rodriguez, A. M. T., Díaz, A., Ruíz, D. P., & Prada, B. L. (2019). Fulminant Progressive Brainstem Encephalitis as Initial Manifestation of NeuroBechet's Disease. International Journal of Rare Diseases & Disorders. https://doi.org/10.23937/2643-4571/1710012
540. Rodriguez, G., & Pinto, R. C. (2010). Lepra neural primaria: definición y criterios de manejo. Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica.
541. Romero-Luna, G., Mejía‐Pérez, S. I., Ramírez-Cruz, J., Aguilar-Hidalgo, K. M., Ocampo-Díaz, K. M., Moscardini-Martelli, J., Ramírez-Stubbe, V., & Santellán-Hernández, J. O. (2022). Schizophrenia-Like Psychosis Presented in a Patient With a Temporal Lobe Tumor: A Case Report. Cureus. https://doi.org/10.7759/cureus.29034
542. Rosebush, P. I., Garside, S., Levinson, A. J., & Mazurek, M. F. (1999). The Neuropsychiatry of Adult-Onset Adrenoleukodystrophy. Journal of Neuropsychiatry. https://doi.org/10.1176/jnp.11.3.315
543. Rosenberg, P. B. (2017). What are the First Signs and Symptoms of Dementia?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199959549.003.0003
544. Rossi, M., Farcy, N., Starkstein, S., & Merello, M. (2019). Nosology and Phenomenology of Psychosis in Movement Disorders. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.12882
545. Rostovschikov, V. V., Ivanchuk, E. G., & Rostovschikova, S. I. (2020). The features of psychopathology and cognitive impairments in various variants of the psychoorganic syndrome. Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery). https://doi.org/10.33920/med-01-2009-07
546. Ruberg, M., France‐Lanord, V., Brugg, B., Hunot, S., Anglade, P., Damier, P., Faucheux, B., & Agid, Y. (1997). Parkinson's Disease, Apoptosis, and Oxidative Stress. CRC Press eBooks. https://doi.org/10.1201/9781482292213-42
547. Ruthirago, D., Julayanont, P., & Rassameehiran, S. (2016). Acute porphyrias and porphyric neuropathy. DOAJ (DOAJ: Directory of Open Access Journals).
548. Ruthirago, D., Julayanont, P., Rassameehiran, S., & Abstract, M. (2016). Acute porphyrias and porphyric neuropathy. The Southwest Respiratory and Critical Care Chronicles. https://doi.org/10.12746/swrccc2016.0415.197
549. Ryan, C. M. (2005). Neurological manifestations of electrical trauma. https://doi.org/10.1109/iembs.2004.1404519
550. S.P., A. (2016). Neuropsychiatric Manifestations as the Presentation of Addison’s Disease Masquerading the Illness. Journal of Medical Science And clinical Research. https://doi.org/10.18535/jmscr/v4i2.13
551. Saddiqa, D., Khalil, D., Rajput, D. M., Ayaz, D., Munawar, D., & Badshah, D. (2024). Jaw Tremors A Rare Presenting Feature In Early Onset Parkinson's Disease. ASEAN Journal of Psychiatry. https://doi.org/10.54615/2231-7805.24.15(1).342
552. Sagar, H. J. (1996). Psychopharmacology of cognitive impairment in Parkinson's disease. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511601187.034
553. Sahonta, R., Sebastian, I. A., Aaron, S., Prabakhar, A. T., Arthur, A., & Pandian, J. (2022). Eye Signs in Stroke. Annals of Indian Academy of Neurology. https://doi.org/10.4103/aian.aian_157_22
554. Salinas, L., & Barr, W. (2019). Assessment of Traumatic Brain Injuries. Cambridge University Press eBooks. https://doi.org/10.1017/9781108235433.031
555. Salman, M., Ahmed, M. N., Wahajuddin, S., Ali, A., Ifra, S., Fatima, N., Begum, F., Aijaz, R., Sadaf, M., & Hani, S. U. (2024). The pharmacology and pharmacotherapeutic approach of various neurological disorders. International Journal of Pharmacology and Clinical Research. https://doi.org/10.33545/26647613.2024.v6.i1a.28
556. Samkar, A. V., Kleermaeker, F. G. C. M. D., Riele, M. G. E. T., & Verrips, A. (2017). Negative Myoclonus Induced by Ciprofloxacin.. PubMed. https://doi.org/10.7916/d8qc0fxt
557. Sandbrink, F. (2016). Plexopathies and mononeuropathies. https://doi.org/10.1002/9781118777329.ch103
558. Santiago, A., & Factor, S. A. (2003). Levodopa. CRC Press eBooks. https://doi.org/10.1201/9780203912164-21
559. Santiago, R. M. (2016). Depression in Parkinson's Disease is Associated with a Serotoninergic System Change Secondary to Neuroinflammation. International Journal of Neurology and Neurotherapy. https://doi.org/10.23937/2378-3001/3/6/1061
560. Santos, S. E. T., Landacay, A. D. P., Castillo, D. M. R., Yaguana, J. A. J., & Saltos, M. D. Á. (2023). Síndrome de Guillain Barré con Patrón de Polineuropatía Axonal Motora Aguda (PAMA) en Paciente Masculino de 10 Años. Reporte de Caso. Ciencia Latina Revista Científica Multidisciplinar. https://doi.org/10.37811/cl_rcm.v7i4.7592
561. Sapir, S., & Aronson, A. (1987). Coexisting psychogenic and neurogenic dysphonia: A source of diagnostic confusion. International Journal of Language & Communication Disorders. https://doi.org/10.3109/13682828709088689
562. Saracino, D., Allegorico, L., Barbarulo, A. M., Pollo, B., Giaccone, G., D’Amico, A., D’Incerti, L., Bugiani, O., Iorio, G. D., Sampaolo, S., & Melone, M. A. B. (2018). Neuro-Behçet’s disease presenting as an isolated progressive cognitive and behavioral syndrome. Neurocase. https://doi.org/10.1080/13554794.2018.1561898
563. Sarnat, H. B. (1987). Disturbances of Late Neuronal Migrations in the Perinatal Period. Archives of Pediatrics and Adolescent Medicine. https://doi.org/10.1001/archpedi.1987.04460090046022
564. Saviluoto, A., Stępień, K. M., Das‐Munshi, J., Cook, A. M., Ocak, U., & Barnacle, J. (2020). Advances in Respiratory Emergencies in Neurological Diseases.
565. Scadding, J. G., & Mitchell, D. N. (1985). The Nervous System. Sarcoidosis. https://doi.org/10.1007/978-1-4899-2971-6_14
566. Scarff, J. R., Iftikhar, B., Tatugade, A., Choi, J.-K., & Lippmann, S. (2011). Opsoclonus myoclonus.. PubMed.
567. Schara, U., Alberg, E., Lutz, S., & Kress, W. (2011). SelenoproteinN1-related myopathy: From clinical signs to diagnosis. Neuropediatrics. https://doi.org/10.1055/s-0031-1274098
568. Schildkrout, B. (2014). Delirium. https://doi.org/10.1002/9781394260447.ch2
569. Schildkrout, B. (2014). Disease #45: Normal‐Pressure Hydrocephalus. https://doi.org/10.1002/9781394260447.ch73
570. Schildkrout, B. (2014). Disease #48: Parkinson's Disease. https://doi.org/10.1002/9781394260447.ch76
571. Schildkrout, B. (2014). Disease #68: Vascular Dementia. https://doi.org/10.1002/9781394260447.ch96
572. Schildkrout, B. (2014). Motor Behavior. https://doi.org/10.1002/9781394260447.ch22
573. Schneider, L. S., & Abou‐Saleh, U. B. M. T. (2002). Neurochemistry. https://doi.org/10.1002/0470846410.ch72
574. Schuster, P. (2010). Restriktive Valvulopathie im Rahmen einer Behandlung mit Dopaminagonisten.
575. Schwartz, M. (2019). Neurological Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190862374.003.0021
576. Schwartz, O., Kurlemann, G., Abels, C., & Fiedler, B. (2008). Autosomal dominant chin myoclonus. Neuropediatrics. https://doi.org/10.1055/s-0029-1215764
577. Schülke, R., Liepach, K., Brömstrup, A., Folsche, T., Deest, M., Bleich, S., Neyazi, A., Frieling, H., & Maier, H. B. (2022). Neurological soft signs are increased in major depressive disorder irrespective of antidepressant treatment. Pharmacopsychiatry. https://doi.org/10.1055/s-0042-1757665
578. Seibyl, J. (2022). α-Synuclein PET and Parkinson Disease Therapeutic Trials: Ever the Twain Shall Meet?. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.122.263918
579. Sekhniashvili, M., Toyka, K. V., & Baum, P. (2024). Elektrophysiologische Aspekte in der Diagnostik und Pathophysiologie der Critical Illness Polyneuromyopathie (CIPNM). Klinische Neurophysiologie. https://doi.org/10.1055/a-2306-0086
580. Selbæk, G. (2016). Psychosis in Dementia. Neuropsychiatric symptoms of neurological disease. https://doi.org/10.1007/978-3-319-39138-0_10
581. Seltzer, B. (2007). Cognitive Complaints: Their Role in Detecting MCI and Dementia.
582. Seltzer, L. E., & Scher, M. S. (2014). Neonatal seizures in the era of therapeutic hypothermia. Neurology. https://doi.org/10.1212/wnl.0000000000000297
583. Selvarajah, D., Sloan, G., & Tesfaye, S. (2020). Diabetic Neuropathy. https://doi.org/10.1002/9781119445821.ch5
584. Sen, A., & Johnson, M. R. (2020). Epilepsy in later childhood and adulthood. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0575
585. Seok, J. I., Lee, D. K., Kang, M. G., & Park, J. H. (2007). Neuropsychological Findings of Extrapontine Myelinolysis without Central Pontine Myelinolysis. Behavioural Neurology. https://doi.org/10.1155/2007/980643
586. Sethi, K. D. (2002). Clinical aspects of Parkinson disease. Current Opinion in Neurology. https://doi.org/10.1097/00019052-200208000-00009
587. Sethi, K. D. (2003). Clinical aspects of Parkinson disease. Current Opinion in Internal Medicine. https://doi.org/10.1097/00132980-200302010-00004
588. Shababi, M., Lorson, C. L., & Rudnik‐Schöneborn, S. (2013). Spinal muscular atrophy: a motor neuron disorder or a multi‐organ disease?. Journal of Anatomy. https://doi.org/10.1111/joa.12083
589. Shafiya, S., Teja, B. S., Tejaswini, T., Dhanush, P., & Nadendla, R. (2014). NONMOTOR COMPLICATIONS OF PARKINSON DISEASE. Indo American Journal of Pharmaceutical Research.
590. Shalaby, T., Papoutsos, C., Tiemens, L., Crossingham, I., & Williamson, C. (2012). Exertional Syncope as a presenting feature in Guillain-Barré syndrome. Acute Medicine Journal. https://doi.org/10.52964/amja.0581
591. Sharma, U., Anjali, S., Surendra, V., Taj, N., & Manjunatha, P. M. (2019). Parkinson’s Disease: A Brief Outlook.
592. Shaughnessy, A. F. (2020). Some Drugs Slightly Improve Cognition in People with Dementia; Effects on Behavioral or Psychological Symptoms Remain Unclear.. PubMed.
593. Sherer, T., Betarbet, R., & Greenamyre, J. T. (2001). Pesticides and Parkinson’s Disease. The Scientific World JOURNAL. https://doi.org/10.1100/tsw.2001.35
594. Shibasaki, H., Hallett, M., Bhatia, K. P., Reich, S. G., & Balint, B. (2020). Disorders of Increased Muscle Stiffness or Overactivity. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190865047.003.0009
595. Shields, C. G. (1985). Alcoholic polyneuropathy. Muscle & Nerve. https://doi.org/10.1002/mus.880080302
596. Shogbesan, G., Schroeder, H. W., Newallo, D., & Hall, L. T. (2023). Molecular Imaging of Parkinson’s Disease. Exon Publications eBooks. https://doi.org/10.36255/molecular-imaging-of-parkinsons-disease
597. Shorvon, S. (1987). Intensive Neurodiagnostic Monitoring. (Advances in Neurology Vol 46).. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.50.9.1247-a
598. Shults, C. W. (2003). Treatments of Parkinson Disease. Archives of Neurology. https://doi.org/10.1001/archneur.60.12.1680
599. Shuxratovich, S. S., Musurmonovich, A. S., & Shodiyorovich, N. L. (2020). Neuroses And The Factors Which Contribute To It. The American Journal of Medical Sciences and Pharmaceutical Research. https://doi.org/10.37547/tajmspr/volume02issue11-24
600. Sibley, W. A. (1974). Diagnosis and Treatment of Epilepsy: Overview and General Principles. PEDIATRICS. https://doi.org/10.1542/peds.53.4.531
601. Siciliano, M., Micco, R. D., Sant’Elia, V., Goldman, J. G., Chiorri, C., Silvestro, M., Russo, A. G., Caiazzo, G., Esposito, F., & Tessitore, A. (2024). Cognitive and Morphometric Features of Mild Cognitive Impairment Reversion in Early Patients with Parkinson’s Disease. Parkinsonism & Related Disorders. https://doi.org/10.1016/j.parkreldis.2024.107077
602. Sinard, J. H., & Hedreen, J. C. (1995). Neuronal loss from the subthalamic nuclei in a patient with progressive chorea. Movement Disorders. https://doi.org/10.1002/mds.870100313
603. Singh, R., & Pandey, S. (2022). Movement Disorder in Demyelinating Disease. Annals of Indian Academy of Neurology. https://doi.org/10.4103/aian.aian_64_22
604. Sivan, M., Phillips, M., Baguley, I., & Nott, M. (2019). Disorders of the peripheral nerves. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198785477.003.0033
605. Slegers, R. J., Vlis, T. A. B. V. D., Ackermans, L., Hoeben, A., Postma, A. A., Compter, I., Hoeijmakers, J. G. J., Beckervordersandforth, J., Broen, M. P. G., & Schijns, O. (2021). Myasthenia gravis after glioblastoma resection: paraneoplastic syndrome or coincidence? A unique case report and review of the literature. Acta Neurochirurgica. https://doi.org/10.1007/s00701-021-05035-3
606. Smith, M. E. (2005). Mental Retardation Associated with Other Neurological Defects. https://doi.org/10.1093/oso/9780195174328.003.0005
607. Sn, L. (2003). [Importance of initial status of the nervous system in the developing of low intensity EMF exposure neuro-effects].. PubMed.
608. Snow, B. J. (2003). Objective measures for the progression of Parkinson's disease. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.74.3.287
609. Solas, G., Bustamante, P., & Grandez, K. (2011). Neurodegenerative Disease Monitoring Using a Portable Wireless Sensor Device. InTech eBooks. https://doi.org/10.5772/29814
610. Solorzano, J. M. M., Quijije, J. K. L., Pin, T. D. R. M., & Vera, J. V. C. (2020). Causas y efectos de los pacientes diagnosticados con el mal de Parkinson. RECIMUNDO. https://doi.org/10.26820/recimundo/4.(4).octubre.2020.496-508
611. Somjen, G. G. (2004). Mechanism of Early, Reversible Hypoxic Synaptic Failure. https://doi.org/10.1093/oso/9780195151718.003.0018
612. Song, M., Lazaro, R. P., Principe, L., & Parsons, D. F. (1987). High-voltage electron microscopic study in the syndrome of myalgia and cramps. Proceedings annual meeting Electron Microscopy Society of America. https://doi.org/10.1017/s042482010012744x
613. Song, Y.-M. (2020). Traumatic Brain Injury-associated Hypopituitarism-A Case Report with Mini Review. 內科學誌. https://doi.org/10.6314/jimt.202010_31(5).09
614. Soni, R., Delvadia, P., Joharapurkar, A., & Shah, J. (2023). Uncovering Novel Therapeutic Targets for Parkinson’s Disease. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.3c00084
615. Sonnen, J. A., Keene, C. D., Hevner, R. F., & Montine, T. J. (2009). Molecular Pathology: Neuropathology. Molecular Pathology. https://doi.org/10.1016/b978-0-12-374419-7.00027-5
616. Souto, F. M. S., Vasconcellos, J. P. C. D., Melo, M. B. D., Sartorato, E. L., & Moura, F. C. (2017). Differentiating Leber Hereditary Optic Neuropathy from Normal-Tension Glaucoma. Neuro-Ophthalmology. https://doi.org/10.1080/01658107.2017.1279185
617. Soyka, M. (2005). Alkoholabhängigkeit – Neuropsychiatrische Komplikationen. Suchttherapie. https://doi.org/10.1055/s-2005-923723
618. Spiegel, E. P., & Vanderploeg, R. D. (2010). Postconcussion Syndrome. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0696
619. Stacy, M., & Jakel, R. J. (2014). Parkinson&amp;rsquo;s disease psychosis. Journal of Parkinsonism and Restless Legs Syndrome. https://doi.org/10.2147/jprls.s40946
620. Stamelou, M., Sheerin, U., Wood, N., & Bhatia, K. P. (2014). The entity of parkinsonism and associated lipomatosis. Neurology. https://doi.org/10.1212/wnl.0000000000000937
621. Stancu, P., d'Esneval, M., Assal, F., Fleury, V., Eshmawey, M., & Unschuld, P. G. (2024). Symptômes psychiatriques de la démence à corps de Lewy. Revue Médicale Suisse. https://doi.org/10.53738/revmed.2024.20.892.1958
622. Stanković, I., & Wenning, G. K. (2014). Neuropsychiatric Manifestations in Atypical Parkinsonian Syndromes. Neuropsychiatric symptoms of neurological disease. https://doi.org/10.1007/978-3-319-09537-0_7
623. Steffens, D. C., Fahed, M., Manning, K. J., & Wang, L. (2022). The neurobiology of apathy in depression and neurocognitive impairment in older adults: a review of epidemiological, clinical, neuropsychological and biological research. Translational Psychiatry. https://doi.org/10.1038/s41398-022-02292-3
624. Steinhausen, H., & Gillberg, C. (2006). Brain disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511543807.002
625. Stella, F., Canineu, P. R., Souza, L. C. D., & Forlenza, O. V. (2014). C URRENT OPINION Neuropsychiatric symptoms in the prodromal stages of dementia.
626. Stella, F., Radanovic, M., Balthazar, M. L. F., Canineu, P. R., Souza, L. C. D., & Forlenza, O. V. (2014). Neuropsychiatric symptoms in the prodromal stages of dementia. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0000000000000050
627. Stevens, J. S., Harnett, N. G., Lebois, L. A. M., Rooij, S. J. V., Ely, T. D., Roeckner, A. R., Vincent, N., Beaudoin, F. L., An, X., Zeng, D., Neylan, T. C., Clifford, G. D., Linnstaedt, S. D., Germine, L., Rauch, S. L., Lewandowski, C., Storrow, A. B., Hendry, P. L., Sheikh, S., ... Ressler, K. J. (2021). Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2021.20101526
628. Stevens, R. D., Sharshar, T., & Ely, E. W. (2013). Diagnosis of Brain Dysfunction. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139248822.026
629. Stone, J., & Carson, A. (2015). Conversion Disorder/Functional Neurological Disorder. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp009
630. Stone, J., Pal, S., Blackburn, D., Reuber, M., Thekkumpurath, P., & Carson, A. (2015). Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-150430
631. Stultz, D., Osburn, S., Burns, T., Gills, T., Welch, D., Shaffer, C., Walton, R., Cope, A., & Pawlowska-Wajswol, S. (2021). 508 Narcolepsy Associated With a History of Head Injury: A Retrospective Review. SLEEP. https://doi.org/10.1093/sleep/zsab072.507
632. Su, J., Chen, T., Zhang, S., Cai, B., & Liu, Y. (2019). Research progress on non motor symptoms of Parkinson′s disease. Zhongguo yishi zazhi. https://doi.org/10.3760/cma.j.issn.1008-1372.2019.04.042
633. Suarte, L. A. M., Oliveira, R. F. L. D., Maia, D. C., Schneiberg, S., & Santana, L. S. (2014). Tratamento fisioterapêutico na criança hipotônica. Semana de Pesquisa e Extensão da Universidade Tiradentes - SEMPESq-SEMEX.
634. Suh, Y., Gandhi, J., Seyam, O., Jiang, W., Joshi, G., Smith, N. L., & Khan, S. A. (2019). Neurological and neuropsychiatric manifestations of porphyria. International Journal of Neuroscience. https://doi.org/10.1080/00207454.2019.1655014
635. Suharti, S. (2020). Patofisiologi Penurunan Kognitif pada Penyakit Parkinson. UMI Medical Journal. https://doi.org/10.33096/umj.v5i1.76
636. Sushmitha, S. C., Balaprabha, G. R., & Rao, T. R. (2022). Moyamoya Disease: A Review of Literature. International Journal of Pharmaceutical Sciences Review and Research. https://doi.org/10.47583/ijpsrr.2022.v76i02.008
637. Sutton, G. P. (2010). Verbal and visual learning and memory deficits as trait markers for psychosis in bipolar disorder. https://doi.org/10.34917/2197490
638. Sveinbjörnsdóttir, S. (2016). The clinical symptoms of Parkinson's disease. Journal of Neurochemistry. https://doi.org/10.1111/jnc.13691
639. Swann, A. C. (2009). Pharmacologic Mood Destabilization: <i>Case Vignettes</i>. CNS Spectrums. https://doi.org/10.1017/s1092852900003898
640. SÖNMEZ, İ., MUT, S. E., & Bozkurt, A. İ. (2016). Psychiatric Symptoms and Disorders in Multiple Sclerosis: Review. Turkiye Klinikleri Journal of Neurology. https://doi.org/10.5336/neuro.2016-51118
641. Tabaquim, M. D. L. M., & Joaquim, R. M. (2013). FUNÇÕES NEUROPSICOLÓGICAS NA PARALISIA CEREBRAL. ARCHIVES OF HEALTH INVESTIGATION.
642. Takahashi, T., Sasabayashi, D., Yücel, M., Whittle, S., Suzuki, M., Pantelis, C., Malhi, G. S., & Allen, N. B. (2024). Gross anatomical features of the insular cortex in affective disorders. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2024.1482990
643. Tan, C., Lingam, G., Rahmat, K., Abdullah, S., Tan, A. H., Tai, M. S., Ramli, N., Thong, W. K., & Tan, C. T. (2015). Primary Angiitis of the Central Nervous System with Myelopathy as Initial Clinical Presentation.
644. Tan, E., & Ondo, W. G. (2001). Motor restlessness.. PubMed.
645. tefanec, D. Š., Puharić, Z., Mrkonjić, R., Bis, S., & tefoković, J. M.-Š. (2016). „Javnozdravstveni značaj Parkinsonove bolesti-prikaz slučaja“. Hrvatski časopis za javno zdravstvo.
646. Terkelsen, A. J., Hansen, J., Klostergaard, A., OTTO, M. A., Mølgaard, H., Hvas, C. L., Krogh, K., Kirkeby, H. J., Madsen, L. B., Andersen, H., & Jensen, T. S. (2018). [Neurogenic autonomic dysfunction in primary amyliodosis].. Research Portal Denmark.
647. Teune, L. K., & Leenders, K. L. (2012). Molecular Imaging in Parkinson’s Disease. Neuromethods. https://doi.org/10.1007/7657_2012_51
648. Thakur, N., Black, M., Russo, S. N., & Koenig, M. K. (2022). Neurometabolic Diseases. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197574317.003.0020
649. Thakurathi, N., & Henderson, D. C. (2012). Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder. Evidence-Based Mental Health. https://doi.org/10.1136/ebmental-2012-100740
650. Thase, M. E. (1998). Depression, sleep, and antidepressants.. PubMed.
651. Thekkethil, D. P., Sreedevi, S., & Menon, B. K. (2024). Psychiatric Camouflage: A Case Series. Cureus. https://doi.org/10.7759/cureus.72912
652. Thibaut, F. (2018). Psychiatric disorders: neurodevelopmental disorders, neurodegenerative disorders, or both?. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2018.20.4/fthibaut
653. Thiels, C., Köhler, C., Weigt-Usinger, K., Richterich, A., & Lücke, T. (2011). Dissociative gait disturbance versus Guillain-Barré-Syndrom -pitfalls in clinical presentation and diagnostics. Neuropediatrics. https://doi.org/10.1055/s-0031-1274099
654. Thobois, S., & Broussolle, E. (2005). [Circumstances of Parkinson's disease diagnosis].. PubMed.
655. Thomsen, T., & Miyasaki, J. M. (2012). Psychogenic Movement Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-120-2_7
656. Thoonen, G., Noordam, C., & Burgt, C. V. D. (2003). [The Noonan syndrome from a pediatric perspective].. PubMed.
657. Tisel, S. M., & Klassen, B. T. (2021). Hypokinetic Movement Disorders: Parkinson Disease. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0069
658. Tolosa, E., Martı́, M. J., & Compta, Y. (2012). Dystonic symptoms associated with parkinsonian disorders. CRC Press eBooks. https://doi.org/10.3109/9781841848525-21
659. Torack, R. M., & Morris, J. C. (1988). The Association of Ventral Tegmental Area Histopathology With Adult Dementia. Archives of Neurology. https://doi.org/10.1001/archneur.1988.00520290025008
660. Torrez, R. D. A., Mercado, A. N. F., Vargas, K. P. C., & Luza, P. L. (2012). Necrosis del cuerpo calloso: Síndrome de Marchiafava - Bignami. DOAJ (DOAJ: Directory of Open Access Journals).
661. Toyoshima, Y., Takahashi, H., Katada, S., Kojima, N., Tada, M., Tani, T., Koike, R., Nozawa, T., Aida, I., Nakajima, T., Onodera, O., & Kakita, A. (2021). Parkinson's disease and parkinsonism: Clinicopathological discrepancies on diagnosis in three patients. Neuropathology. https://doi.org/10.1111/neup.12777
662. Trabacca, A., Ferrante, C., Oliva, M. C., Fanizza, I., Gallo, I., & Rinaldis, M. D. (2024). Update on Inherited Pediatric Motor Neuron Diseases: Clinical Features and Outcome. Genes. https://doi.org/10.3390/genes15101346
663. Tredici, K. D., & Braak, H. (2012). Lewy pathology and neurodegeneration in premotor Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.24921
664. Treede, R. (2012). Peripheral and Central Mechanisms of Neuropathic Pain. Oxford University Press eBooks. https://doi.org/10.1093/med/9780195394702.003.0002
665. Trimmer, P. A., Tuttle, J. B., Sheehan, J. P., & Bennett, J. P. (1996). Mechanisms of Selective Neuronal Vulnerability to 1-Methyl-4-Phenylpyridinium (MPP+) Toxicity. Neurodegenerative Diseases. https://doi.org/10.1007/978-1-4899-0209-2_53
666. Tt, S., Mj, K., & Friis, M. (1996). [Progressive myoclonic epilepsy].. PubMed.
667. Tuchman, R., Moshé, S. L., & Rapin, I. (2005). Trastornos del neurodesarrollo y epilepsia. Revista de Neurología. https://doi.org/10.33588/rn.40s01.2004649
668. Turgut, B. (2017). Neuro-ophthalmological emergency disorders: A general view. International Journal of Clinical and Experimental Ophthalmology. https://doi.org/10.29328/journal.ijceo.1001009
669. Turpin, C., Masson, M. H., & Baumann, N. (1991). Clinical Aspects of Niemann-Pick Type C Disease in the Adult. Developmental Neuroscience. https://doi.org/10.1159/000112177
670. Tyack, C. (2022). Insomnia in childhood. Oxford University Press eBooks. https://doi.org/10.1093/med/9780192848253.003.0020
671. Tysnes, O., & Vilming, S. T. (2008). [Atypical parkinsonism].. PubMed.
672. Tüğdür, M., Kaya, D., Tol, C., Yamazhan, T., Pullukçu, H., & Taşbakan, M. (2024). NÖROSİFİLİZ: ÜÇ OLGU. ANKEM Dergisi. https://doi.org/10.54962/ankemderg.1441902
673. Uchida, Y., Nishimaki, K., Soldan, A., Moghekar, A., Albert, M., & Oishi, K. (2024). Acceleration of Brain Atrophy and Progression From Normal Cognition to Mild Cognitive Impairment. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.41505
674. Valikova, T. A., Tsyrenzhapova, R. B., & Bichik, A. B. (2009). Clinical features of supranuclear palsy. Bulletin of Siberian Medicine. https://doi.org/10.20538/1682-0363-2009-3(2)-78-82
675. Vanier, M. T. (2010). Niemann-Pick disease type C. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-5-16
676. Varghese, L. S., Ruzda, K., Shabeeb, N., Meghan, & Hainas, K. (2022). Binocular Vision Function and Migraine: A Review. International Journal For Multidisciplinary Research. https://doi.org/10.36948/ijfmr.2022.v04i06.1144
677. Vaughan, C., & Goldman, J. G. (2012). Psychosis and Parkinson’s Disease. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-835-5_6
678. Velasco-Rey, M. C., Sánchez-Muñoz, M., Lopez, M., Trujillo-Borrego, A., & Sánchez-Bonome, L. (2012). Psychotic depression induced by Obstructive Sleep Apnoea Syndrome (OSAS): a case reported.. PubMed.
679. Ventura, M. I., Edwards, J. D., & Barnes, D. E. (2015). More than just a movement disorder. Neurology. https://doi.org/10.1212/wnl.0000000000002158
680. Verma, R., Praharaj, H. N., Raut, T., & Rai, D. (2013). Propriospinal myoclonus: is it always psychogenic?. BMJ Case Reports. https://doi.org/10.1136/bcr-2013-009559
681. Vermeulen, G., Seidl, R., Mercimek‐Mahmutoglu, S., Rotteveel, J. J., Scheper, G. C., & Knaap, M. S. V. D. (2005). Fright is a provoking factor in vanishing white matter disease. Annals of Neurology. https://doi.org/10.1002/ana.20418
682. Vernino, S., Geschwind, M. D., & Boeve, B. F. (2007). Autoimmune Encephalopathies. The Neurologist. https://doi.org/10.1097/01.nrl.0000259483.70041.55
683. Vigevano, F., & Bartuli, A. (2002). Infantile epileptic syndromes and metabolic etiologies.. PubMed.
684. Vijayan, J., & Alexander, M. (2005). Critical illness neuropathy. Indian Journal of Critical Care Medicine. https://doi.org/10.4103/0972-5229.16267
685. Visser, A. (2012). Febrile Seizures and Other Paroxysmal Events in Early Childhood: The generation R Study.
686. Vogel, F. (1985). Phenotypic deviations in heterozygotes of phenylketonuria (PKU).. PubMed.
687. Vukmir, R., Valeriano, J., & Oblack, A. (2023). Brain Death. Cambridge University Press eBooks. https://doi.org/10.1017/9781316338513.027
688. Wada, N. (2019). Autonomic Disorders Associated with Parkinson's Disease. The Japanese Journal of Rehabilitation Medicine. https://doi.org/10.2490/jjrmc.56.204
689. Wakode, S., Hulke, S., Wakode, N., Pathak, T., Shrivastava, R., Thakare, A., & Malhotra, V. (2022). Assessing Neurocognition (P300) and Correlating Them to Depression Rating Scales in Patients With Major Depressive Disorder. Cureus. https://doi.org/10.7759/cureus.31084
690. Walker, M. C., & Sander, J. W. (2011). Epilepsy and Sleep Disorders. CRC Press eBooks. https://doi.org/10.1201/b13388-13
691. Walsh, R. A., Bie, R. M. A. D., & Fox, S. H. (2013). Nonmotor Symptoms in Parkinson’s Disease. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199927524.003.0006
692. Walvoord, E. C., & Eugster, E. A. (2002). Normal and Abnormal Growth. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-156-5_3
693. Wang, A. K., & Rutkove, S. B. (2007). Electrophysiology of Polyneuropathy. Humana Press eBooks. https://doi.org/10.1007/978-1-59745-271-7_16
694. Wang, H.-P., Wong, L., Hsu, C., Hu, S., Chu, Y.-J., & Lee, W. (2021). Eye motor manifestations in children with neurometabolic disorders. Journal of the Formosan Medical Association. https://doi.org/10.1016/j.jfma.2021.09.003
695. Warren, K., Katakam, J., & Espiridion, E. D. (2019). Acute-onset Mania in a Patient with Non-small Cell Lung Cancer. Cureus. https://doi.org/10.7759/cureus.5436
696. Watson, C., Kirkcaldie, M., & Paxinos, G. (2010). When things go wrong–brain disease and injury. Brain. https://doi.org/10.1016/b978-0-12-373889-9.50009-7
697. Weerkamp, N. J., Ommen-Nijhof, A. V., & Tissingh, G. (2009). Non-Motor Symptoms of Parkinson's Disease. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199237234.001.0001
698. Wei, D. Y., & Drake, M. J. (2015). Undiagnosed neurological disease as a potential cause of male lower urinary tract symptoms. Current Opinion in Urology. https://doi.org/10.1097/mou.0000000000000243
699. Weintraub, D., & Burn, D. J. (2011). Parkinson's disease: The quintessential neuropsychiatric disorder. Movement Disorders. https://doi.org/10.1002/mds.23664
700. Werman, D. S. (1977). On the Occurrence of Incest Fantasies. The Psychoanalytic Quarterly. https://doi.org/10.1080/21674086.1977.11926799
701. Wierenga, C. E., & Bondi, M. W. (2011). Dementia and Alzheimer's Disease: What We Know Now. Generations.
702. Wiffen, B., & David, A. S. (2009). Metacognition, mindreading, and insight in schizophrenia. Behavioral and Brain Sciences. https://doi.org/10.1017/s0140525x09000806
703. Wijdicks, E. F. M. (2014). Neurologic Disorders in Film. CRC Press eBooks. https://doi.org/10.1201/b17682-3
704. Wijdicks, E. F. M. (2016). Moving, Jerking, and Spasm. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190259556.003.0008
705. Wilbur, J. (2023). Dementia: Dementia Types.. PubMed.
706. Willis, M. (2020). #WordsMatter—Communicating the voluntary‐to‐involuntary spectrum in conversion disorder. The Brown University Child and Adolescent Behavior Letter. https://doi.org/10.1002/cbl.30460
707. Wills, A. J. (2006). The neurology of enteric disease. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2005.085365
708. Wong, J., Halliday, G. M., & Kim, W. S. (2014). Exploring Myelin Dysfunction in Multiple System Atrophy. Experimental Neurobiology. https://doi.org/10.5607/en.2014.23.4.337
709. Xiao, J., & Cheng, Y. (2009). Pathophysiological mechanisms of cognitive impairment caused by chronic cerebral hypoperfusion. Int J Cerebrovasc Dis. https://doi.org/10.3760/cma.j.issn.1673-4165.2009.08.012
710. Yadav, B. (2021). Risk Factors for Dementia and Cognitive Impairments.
711. Yadav, L., Khosla, P., Taneja, V., & Dessai, R. (2023). Primary adrenal insufficiency presenting with neuropsychiatric illness. International Journal of Research in Medical Sciences. https://doi.org/10.18203/2320-6012.ijrms20232447
712. Yager, J. (2015). Cholinergic and Anticholinergic Balances Affect Working Memory in Schizophrenia. Journal watch. https://doi.org/10.1056/nejm-jw.na37521
713. Yakhia, M., König, A., Flier, W. M. V. D., Friedman, L., Robert, P., & David, R. (2014). Actigraphic Motor Activity in Mild Cognitive Impairment Patients Carrying Out Short Functional Activity Tasks: Comparison between Mild Cognitive Impairment with and without Depressive Symptoms. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-131691
714. Yanagisawa, N. (1998). [Motor and cognitive functions of the basal ganglia].. PubMed.
715. Yang, J. S., Cho, Y. J., Kang, S. H., & Choi, E. H. (2015). Neuralgic Amyotrophy Manifesting as Mimicking Posterior Interosseous Nerve Palsy. Journal of Korean Neurosurgical Society. https://doi.org/10.3340/jkns.2015.58.5.491
716. Yang, T., Guo, R., Ofengeim, D., Hwang, J.-Y., Zukin, R. S., Chen, J., & Zhang, F. (2021). Molecular and Cellular Mechanisms of Ischemia-Induced Neuronal Death. Stroke. https://doi.org/10.1016/b978-0-323-69424-7.00005-3
717. Yasuda, T., Hatakeda, J., & Yoshimasu, H. (2018). [Assessments and Treatments for Neurological Symptoms That Do Not Match Organic Findings].. PubMed. https://doi.org/10.11477/mf.1416201117
718. Yen, M. Y., Tirtayasa, K., & Sutjana, D. P. (2013). RATIONAL MANAGEMENT OF PARKINSON’S DISEASE.
719. Yenişehir, S., Batur, V., Karakaya, İ. Ç., & Karakaya, M. G. (2020). Patient-Reported and Performance-Based Outcome Measures for Functional Mobility and Activity Limitation in Individuals with Parkinson's Disease. Anadolu Kliniği Tıp Bilimleri Dergisi. https://doi.org/10.21673/anadoluklin.622194
720. Yi, S., Wang, L., Wang, H., Ho, M. S., & Zhang, S. (2022). Pathogenesis of α-Synuclein in Parkinson’s Disease: From a Neuron-Glia Crosstalk Perspective. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms232314753
721. Yin, D., Chen, S., & Liu, J. (2021). Sleep Disturbances in Autoimmune Neurologic Diseases: Manifestation and Pathophysiology. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2021.687536
722. Yin, J., Yu, Y., & Liu, W. (2019). Neuron-antibody mediated movement disorders. Chin J Neurol. https://doi.org/10.3760/cma.j.issn.1006-7876.2019.07.014
723. Yoo, J., Kim, N.-M., Sung, W.-K., Myeong, J.-C., Yun, S., Lee, D., Lim, M., & Sheen, D. (2015). A Case of Guillain-Barre Syndrome in a Patient of Behçet's Disease. Journal of Rheumatic Diseases. https://doi.org/10.4078/jrd.2015.22.4.246
724. You, S. J. (2012). Cognitive function of idiopathic childhood epilepsy. Korean Journal of Pediatrics. https://doi.org/10.3345/kjp.2012.55.5.159
725. Yuanxia, C., Wang, F., Jing, Z., Luo, H., & Shuyan, J. (2013). xin sheng er gao dan hong su xue zheng dao zhi ting shen jing bing de lin chuang yan jiu jin zhan. Medical Journal of Trauma and Disability.
726. Zesiewicz, T., Sullivan, K. L., & Hauser, R. A. (2006). Nonmotor symptoms of Parkinson’s disease. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.6.12.1811
727. Zhang, Y. (2021). Investigation of the Effects of SIRT1 and SIRT2 Modulators in Neuroinflammatory Models of Depression. https://doi.org/10.25904/1912/4137
728. Zhou, K., Chow, P. C., & Lim, S. (2024). A Criminal Case of Hypersexuality and Parkinson’s Disease. Neurology and Neuroscience. https://doi.org/10.33425/2692-7918.1071
729. Zhou, S., & Patel, A. (2022). Pituitary Apoplexy Presenting as Acute Headache. Canadian Journal of General Internal Medicine. https://doi.org/10.22374/cjgim.v17i2.588
730. Zifkin, B. G. (2002). Les circonstances de mort de l'épileptique. Epilepsies.
731. Zorkina, Y., Zubkov, E., Morozova, А., Abramova, O., & Karimova, O. S. (2020). EFFECTS OF ELECTROCONVULSIVE STIMULATION IN RATS WITH 6-OHDA INDUCED HEMIPARKINSONISM. BIOTECHNOLOGY STATE OF THE ART AND PERSPECTIVES. https://doi.org/10.37747/2312-640x-2020-18-184-186
732. Zwicker, A., MacKenzie, L. E., Drobinin, V., Vallis, E. H., Patterson, V. C., Stephens, M., Cumby, J., Propper, L., Abidi, S., Bagnell, A., Schultze‐Lutter, F., Pavlová, B., Alda, M., & Uher, R. (2019). Basic symptoms in offspring of parents with mood and psychotic disorders. BJPsych Open. https://doi.org/10.1192/bjo.2019.40
733. Šonka, K. (2019). Sleep and its disturbances in neurology.. PubMed.